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1. Introduction 
1.1 D-Amino acids in mammalian tissue 
Every amino acid (except glycine) can occur in two isomeric forms, because 
of the possibility of forming two different enantiomers (stereoisomers) around the 
central carbon atom. By convention, they are called L- and D- forms, analogous to left-
handed and right-handed configurations (Figure 1). 
 
Figure 1.1: example of D- and L- form of amino acids 
Only L-amino acids are manufactured in cells and incorporated into proteins. Some D-
amino acids are found in the cell walls of bacteria, thus conferring protection against 
attacks of protease and microorganisms (Corrigan, 1969). D-amino acids are 
incorporated into the peptides via two different mechanisms. The first mechanism is 
post-translational conversion of L- to D-amino acids within peptides that were 
originally synthesized in ribosomes. The second mechanism requires the activity of 
non-ribosomal peptide (NRP) synthetases, which, unlike ribosomal peptide synthesis, 
generates peptides independent of messenger RNA. While posttranslational 
modification occurs primarily in eukaryotes, NRP synthesis is more frequent in 
bacteria (Cava et al., 2011). In mammals, D-amino acids have only been detected in 
metabolically inert proteins owing to processes of spontaneous racemization occurring 
with age (Fujii, 2002, 2005). Therefore, for many years it was commonly assumed that 
only L-amino acids have a biological role in mammals. However, in the years 80-90 
the refinement of sensitive analytical techniques revealed appreciable concentrations 
of free D-amino acids, such as D-serine (D-Ser) and D-aspartate (D-Asp), in the brain 
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and peripheral organs of rodents and man (Dunlop et al., 1986; Hashimoto et al., 
1992b; Hashimoto et al., 1992a). 
1.2 D-Aspartate in mammals 
The presence of endogenous free D-Asp has been described in mammals such 
as mouse, rat and human, starting from the mid-80s (Dunlop et al., 1986; Neidle and 
Dunlop, 1990; Hashimoto et al., 1993). D-Asp is present both in the central nervous 
system and endocrine glands, appearing with a peculiar temporal occurrence pattern. 
In endocrine glands, D-Asp content increases during post-natal and adult phase, in 
concomitance with their functional maturation, hence the appearance of this D-amino 
acid has been functionally correlated with the synthesis and/or the release of different 
hormones (Furuchi and Homma, 2005; D'Aniello, 2007). In contrast to peripheral 
organs, transient occurrence of D-Asp has been demonstrated in the brain, where it is 
selectively found at very high concentrations during embryo and perinatal phases 
(Dunlop et al., 1986; Neidle and Dunlop, 1990; Hashimoto et al., 1993; Hashimoto et 
al., 1995; Sakai et al., 1998; Wolosker et al., 2000).. Localization of D-Asp was 
analyzed throughout the first post-natal month of life (Wolosker et al., 2000) (Figure 
1.2). Between post-natal day 0 (P0) and P2, D-Asp was found at considerable levels 
in the forebrain and midbrain, and then also in the caudal-most regions of the brain. At 
these perinatal stages, D-Asp is concentrated in neuronal sets of the cerebral cortex, 
hippocampus and cerebellum, which are actively involved in developmental processes. 
At P7, D-Asp immunostaining uniformly decreases in the brain, to almost disappear 
at P28.  
 
Figure 1.2: Localizations of D-Asp during postnatal development. Left Panel: D-Asp was localized by 
immunohistochemistry. At P0, highest levels are observed in the cerebral cortex (Ctx), olfactory bulb 
(Ob) and hippocampus (H). At P2, staining increases in the cerebellum (Cb) and inferior colliculi (IC), 
while levels remain unchanged in the hypothalamus (Hy) and olfactory bulb. Overall levels of D-Asp 
decrease at P7 and P28. Right panel: D-Asp were measured by HPLC in total rat brain and cerebral 
cortex. 
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One important point to keep in mind is that at all phases and in all brain areas, D-Asp 
is exclusively restricted to neuronal population, localized both in cytoplasm and fiber 
tracks, without any evident staining in glia (Schell et al., 1997; Wolosker et al., 2000). 
Surprisingly, HPLC analysis performed on prefrontal cortex (PFC) homogenates from 
fetuses unveiled that D-Asp amount at gestational week 14 even exceeds that of the 
corresponding L-form (Hashimoto et al., 1993). It is noteworthy to highlight that in 
neurosecretory neurons of the rat hypothalamus, D-Asp has been detected in the 
nucleoli, in close association with heterochromatin (Wang et al., 2002). This 
observation prompted authors to hypothesize that this D-amino acid may be involved 
also in the control of gene expression (Wang et al., 2002).  
1.3 Regulation of D-Aspartate levels in mammalian brain 
The specific temporal and regional changes of D-Asp contents in mammalian 
tissues imply the existence of biochemical mechanisms for the precise modulation of 
its endogenous levels. On the other hand, the supposed derivation of D-Asp from 
exogenous sources, such as the diet, or from endogenous metabolically stable proteins 
cannot explain the prenatal peak of occurrence of this D-amino acid in the brain.. In 
this regard, time-dependent accumulation of D-Asp in D-Asp-free pheochromocytoma 
PC12 cells (Long et al., 1998), and conversion of [C14]L-Asp into [C14]D-Asp in 
primary neuronal cell cultures from rats (Wolosker et al., 2000) suggested that this D-
amino acid can be autonomously synthesized in mammalian cells, via a putative Asp 
racemase enzyme (Homma, 2007; Katane and Homma, 2011). A few years ago, a 
mouse pyridoxal 5’-phosphate (PLP)-dependent glutamate-oxalacetate transaminase 
1-like 1 (Got1l1), which substantially converts L-Aspartate (L-Asp) to D-Asp and 
colocalizes with D-Asp in the adult brain, has been identified as the main source of 
endogenous D-Asp in this organ (Kim et al., 2010). On the other side, a recent 
publication has demonstrated that Got1l1 mRNA is undetectable in the brain. 
Moreover, the recombinant enzyme shows L-Asp aminotransferase activity but lacks 
Asp racemase activity. In agreement with biochemical results, knockout mice for 
Got1l1 display D-Asp levels comparable to those of wild-type animals (Tanaka-
Hayashi et al., 2014) suggesting there might be an as yet unknown enzyme for D-Asp 
synthesis. Interestingly, another study has evidenced that D-Asp levels are reduced in 
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the forebrain of serine racemase knockout mice (Srr-KO) (Horio et al., 2013), thus 
suggesting a novel potential unexpected pathway for the generation of D-Asp in the 
brain or that the synthesis of D-Asp is directly related to D-Ser production in the brain.  
If the biosynthesis of D-Asp is still a controversial topic, the existence of an enzyme 
catabolising free D-Asp, D-aspartate oxidase (DDO, EC 1.4.3.1), has long been 
established (Still et al., 1949). DDO is a flavin adenine dinucleotide  (FAD)-containing 
flavoprotein (Van Veldhoven et al., 1991) which oxidizes D-Asp in presence of H2O 
and O2, producing α-oxaloacetate, H2O2 and NH4+ ions (D'Aniello et al., 1993) (Figure 
1.3).  
 
 
Figure 1.3: conversion of D-Asp in α-oxaloacetate by D-aspartate oxidase (DDO). 
 
Besides D-Asp, DDO is able to selectively oxidize in vitro also other bicarboxylic D-
amino acids, such as D-glutamate (D-Glu) and N-methyl D-aspartate (NMDA), while 
it is inactive towards all the other D-amino acids including D-Ser (Setoyama and 
Miura, 1997), that are degraded by the D-amino acid oxidase (DAAO, EC 1.4.3.3), a 
flavoenzyme homologous to DDO (Negri et al., 1992; Pollegioni et al., 2007; Sacchi 
et al., 2012). The protein sequence possesses a functional C-terminal tripeptide for the 
targeting to peroxisomes (Setoyama and Miura, 1997; Amery et al., 1998), where DDO 
is supposed to oxidize D-Asp and release its catabolites (Beard, 1990). Localization of 
this enzyme into catalase-containing organelles like peroxisomes allows the cell to 
safely remove H2O2, a toxic product of D-amino acids metabolism (Katane and 
Homma, 2010). In the brain, DDO is expressed at post-natal phases since its activity 
strongly increases from birth until 6 weeks of life (Van Veldhoven et al., 1991) (Figure 
1.4), and is predominantly localized in neuronal population (Zaar et al., 2002). The 
onset of DDO activity after birth and its progressive increase imply a control of this 
enzyme on the postnatal levels of D-Asp. However, it has been unclear for long time 
whether time-dependent activity of DDO correlates with Ddo gene expression. In this 
regard, recent finding in mice indicates that the gradual decrease of D-Asp content, in 
a time-window between E15 and P60, is accompanied by complementary increased 
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transcription of Ddo gene (Punzo et al., 2016), thus matching with the previously 
reported enhanced postnatal DDO activity (Van Veldhoven et al., 1991). Interestingly, 
the temporal postnatal increase in Ddo mRNA levels is reflected by progressive 
demethylation in the CpG sites of Ddo surrounding the transcription start site (8 CpG 
residues from -363 to +113 bp). This observation seems to have functional impact on 
Ddo gene transcription since treatment with the demethylating agent azacitidine is able 
to substantially trigger Ddo transcription in primary neuronal cultures from embryonic 
cortex that, normally, do not express the gene (Punzo et al., 2016). In agreement with 
a physiological activity of DDO over endogenous free D-Asp, histochemical detection 
in the rat brain shows that DDO expression is reciprocal to D-Asp localization (Schell 
et al., 1997).  
 
 
Figure 1.4: DDO activity during postnatal life in kidney, liver and cerebrum  
 
1.4 Pharmacological influence of D-aspartate on NMDAR-dependent 
transmission 
NMDA subclass of ionotropic glutamate (Glu) receptors has generated for a 
long time an enormous interest in neuroscience due to its implication in developmental 
and physiological neuronal processes (Ikonomidou et al., 2001; Ritter et al., 2002; 
Nacher and McEwen, 2006). In addition, alterations in NMDARs activity have also 
been reported in neuropathological disorders including epilepsy, Alzheimer’s disease 
and schizophrenia (SCZ) (Javitt, 2004; Kalia et al., 2008; Nistico et al., 2012). NMDA 
receptors (NMDARs) are composed of GluN1subunit combined with the different four 
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GluN2 subunits (A-D), where the functional properties of each heteromeric assembly 
strictly depend on the specific subunit composition (Cull-Candy and Leszkiewicz, 
2004). The NMDAR ion channel is permeable to monovalent cations, including Na+ 
and K+ and divalent cations, most notably Ca2+. Moreover, there is a binding site within 
the channel pore for Mg2+. At resting membrane potential, Mg2+ binds to this site 
largely blocking ion flow through the channel. When the membrane is depolarized, 
Mg2+ is expelled from the channel allowing for greatly enhanced passage of ions. 
Activation of NMDAR leads to Ca2+ currents which overall are able to trigger several 
complex intracellular responses, including the activation of guanylate cyclase, release 
of arachidonic acid, translocation and activation of protein kinase C and modulation 
of gene expression (Dingledine et al., 1999; Hardingham and Bading, 2010).  
In the past decades, a considerable number of studies have investigated the molecular 
binding between the different subclasses of L-Glu receptors and various L-Glu 
analogues with potential ligand affinity, in order to find new pharmacological agents 
with agonistic or antagonistic activity. Among these compounds, D-Asp emerged as a 
molecule able to bind NMDARs, owing to a relatively high affinity for their Glu 
binding site (Fagg and Matus, 1984; Monahan and Michel, 1987; Ogita and Yoneda, 
1988; Olverman et al., 1988; Ransom and Stec, 1988). A comparative binding study 
in rat brain membranes demonstrated that the potency of D-Asp to displace the binding 
of the competitive NMDAR antagonist, [H3]AP5, is the same of NMDA and 10-fold 
lower than L-Glu (Olverman et al., 1988). In agreement with these in vitro binding 
assays, voltage-clamp recordings from CA1 pyramidal neurons in mouse hippocampal 
slices indicate that local applications of D-Asp are able to induce inward currents, 
antagonized in a concentration-dependent and reversible manner by competitive and 
non-competitive blockers of NMDARs, such as D-AP5 and MK-801, respectively 
(Errico et al., 2008b) (Figure 1.5).  
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Figure 1.5: Inward currents recorded from CA1 pyramidal neurons of Ddo+/+ mice following local 
pressure application of D-aspartate (arrows), are reduced by D-AP5 in a concentration-dependent and 
reversible manner, and persistently diminished by MK801 (10 μM).  
 
 
However, as shown in figure, both antagonists used do not completely reset the current 
induced by D-Asp. Interestingly, residual D-Asp-dependent currents still persist also 
after the simultaneous perfusion of selective antagonists of NR2A, NR2B and NR2C-
D subunits of NMDARs or even after the application of high concentrations of D-AP5 
or MK-801 (Errico et al., 2008b; Errico et al., 2011b; Errico et al., 2011a), thus 
suggesting the existence of NMDAR-independent currents triggered by this D-amino 
acid. In this respect, it has been shown that D-Asp is able to inhibit kainate-induced 
AMPA receptor currents in acutely isolated rat hippocampal neurons (Gong et al., 
2005). Another study indicates that D-Asp can also activate mGluR5 receptors, 
coupled to polyphosphoinositide hydrolysis, in neonate rat hippocampal and cortical 
slices (Molinaro et al., 2010). Likewise, a recent study performed in dopamine neurons 
of the substantia nigra pars compacta of mice has shown that currents produced by 
D-Asp are mainly dependent by NMDAR but a smaller component is also mediated 
by ionotropic AMPA receptors and metabotropic Glu1/5 receptors (Krashia et al., 
2015). These observations expand the range of potential targets for D-Asp action, 
although the origin of the NMDAR-independent currents stimulated by D-Asp remains 
to be further clarified.  
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1.5 Release and uptake of D-Aspartate 
If D-Asp is actually able to mediate intercellular communication in the brain by 
influencing NMDAR-dependent transmission, then there should be a mechanism to 
allow also the extracellular release and the subsequent reuptake of this D-amino acid. 
Experiments using radiolabeled D-Asp in rat brain slices demonstrated that 
intracellular D-Asp is released upon chemical and electrical stimulation (Savage et al., 
2001). The release of D-Asp to the extracellular environment has been measured from 
D-Asp-containing tissues or cells of the mammalian brain in a Ca2+-dependent manner 
(Davies and Johnston, 1976; Malthe-Sorenssen et al., 1979; Nakatsuka et al., 2001). 
The relevant role of Ca2+ for triggering D-Asp release was unequivocally demonstrated 
in experiments using chelating agents for Ca2+, able to strongly reduce D-Asp efflux 
after exposure to KCl (Wolosker et al., 2000). Besides to a Ca2+-dependent release, 
other studies suggest that also L-Glutamate (L-Glu) transporters may contribute to the 
efflux of intracellular D-Asp via heteroexchange mechanism, as observed in cultures 
of mouse neurons and astrocytes (Anderson et al., 2001; Bak et al., 2003). In addition, 
spontaneous D-Asp release, that is independent of Ca2+-related exocytosis, has also 
been reported (Adachi et al., 2004; Koyama et al., 2006).  
Presynaptic nerve terminals express L-Glu/L-Asp transport systems that utilize a Na+-
dependent mechanism to move excitatory L-amino acids against their concentration 
gradient. The first reports showing high and specific affinity of D-Asp for L-Glu 
transporters (excitatory amino acids transporters, EAATs) came from studies on the 
characterization of transporter systems by means of radiolabeled uptake ligands 
(Davies and Johnston, 1976; Streit, 1980; Storm-Mathisen and Wold, 1981; Wilkin et 
al., 1982; Taxt and Storm-Mathisen, 1984). Subsequent investigations following the 
isolation and cloning of EAAT subtypes have confirmed that all of them are able to 
transport L- and D-Asp in a stereoblind fashion (Palacin et al., 1998).  
Besides the in vitro results reported above, the prerequisite to sustain that D-Asp is 
physiologically involved in NMDAR-related neurotransmission is the demonstration 
that this D-amino acid occurs in the in vivo brain at extracellular level, where it can 
actually stimulate the target receptor. This evidence has recently turned out from a 
microdialysis study demonstrating that D-Asp is present at nanomolar concentrations 
in the extracellular space of the prefrontal cortex of freely moving mice (Punzo et al., 
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2016). Interestingly, when dialysate fraction is collected in a Ca2+-free artificial 
cerebrospinal fluid (ACSF), extracellular D-Asp levels become undetectable, 
suggesting that D-Asp is released in a Ca2+-dependent manner and that the pre-existing 
D-Asp has been efficiently removed from the extracellular space (Punzo et al., 2016). 
Moreover, the lack of DDO in Ddo knockout mice (Ddo-/-) (Errico et al., 2006) leads 
to the concomitant increase of extracellular and total D-Asp content in the PFC, 
indicating that impaired catabolism of D-Asp affects the extracellular release of this 
D-amino acid (Punzo et al., 2016). 
 
1.6 Schizophrenia, NMDARs and D-amino acids 
Schizophrenia (SCZ) is a chronic, severe, debilitating mental illness that affects 
about 1% of the population and generally appears in late adolescence or early 
adulthood. In many cases the disorder develops so slowly that the sufferer does not 
know he/she has it for a long time. With other people it can strike suddenly and develop 
fast.  It is considered to be the result of a complex group of genetic, psychological, and 
environmental factors. SCZ is often described in terms of positive and negative 
symptoms. Positive symptoms are those that most individuals do not normally 
experience but are present in people with schizophrenia. They can include delusions, 
disordered thoughts and speech, and tactile, auditory, visual, olfactory and gustatory 
hallucinations, typically regarded as manifestations of psychosis. Positive symptoms 
generally respond well to medication. Negative symptoms are deficits of normal 
emotional responses or of other thought processes, and respond less well to 
medication. They commonly include flat or blunted affect and emotion, poverty of 
speech (alogia), inability to experience pleasure (anhedonia), lack of desire to form 
relationships (asociality), and lack of motivation (avolition). Of the many 
contemporary theories of SCZ, the most enduring has been the dopamine hypothesis. 
It is based on knowledge of antipsychotic medications, as well as the effects of illicit 
substances such as amphetamines: under the influence of amphetamine the brain is 
flooded with dopamine and norepinephrine and amphetamine-induced psychosis 
closely resembles paranoid SCZ. Using these facts as a starting point, scientists figured 
out that patients with SCZ have excessive dopamine receptors in specific brain regions. 
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On the other hand, glutamatergic models of SCZ were first proposed approximately 
20 years ago (Javitt, 1987), based on the early observation that phencyclidine (PCP), 
ketamine, and related drugs induced SCZ-like psychotic effects, followed later by the 
observation that these compounds induce their unique behavioral effects by blocking 
neurotransmission at NMDARs (Javitt and Zukin, 1991). Since that time, 
neurochemical models based on actions of PCP and ketamine have become 
increasingly well established, with focus on glutamatergic dysfunction as a basis for 
both symptoms and cognitive dysfunction in SCZ. Accordingly, facilitation of 
NMDAR-mediated neurotransmission has been proposed as a strategic therapeutic 
approach in SCZ. Consistent with this idea, several reports have demonstrated the 
clinical benefits of targeting the glycine binding-site of the NMDARs (Coyle et al., 
2002; Millan, 2002).  Nowadays, D-Ser, D-cycloserine and glycine are the most 
promising molecules in SCZ treatment, given their ability to bind and activate this site 
(Cascella et al., 1994; Javitt et al., 1994; Goff et al., 1995; Tsai et al., 1998; Heresco-
Levy et al., 2002; de Bartolomeis et al., 2012). In particular, the clinical interest for D-
Ser has been supported by altered D-Ser metabolism in SCZ patients. In this regard, 
Hashimoto and coworkers found lower concentrations of D-Ser in serum of patients 
with SCZ (Hashimoto et al., 2003). Together with D-Asp, D-Ser is the only D-amino 
acid present at high concentrations in the mammalian brain (Hashimoto and Oka, 
1997). This D-amino acid is generated by the activity of the pyrodoxal 5-phosphate-
dependent serine racemase enzyme (SR) (Wolosker et al., 1999) and its degradation 
occurs via the activity of peroxisomal flavoprotein D-amino acid oxidase (DAAO) 
(Krebs, 1935). To support the neurobiological and clinical interest of this 
unconventional D-amino acid in SCZ physiopathology, genetic and functional studies 
report that the DAAO gene is a marker of susceptibility to SCZ (Labrie et al., 2012). 
Based on the aforementioned observations and considering that also D-Asp, by binding 
glutamate-binding site, acts on the NMDARs as an endogenous agonist, we 
hypothesized that also this D-amino acid may play a role in SCZ. 
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1.7 Mouse models with deregulated higher levels of D-aspartate. 
In order to comprehend the in vivo function of D-Asp and of its catabolic 
enzyme DDO, in the last years a knockout mouse model have been generated through 
the targeted deletion of the Ddo gene (Errico et al., 2006). Measurement of endogenous 
free D-Asp levels by HPLC in the whole brain and in peripheral organs of knockout 
line (Ddo-/-) have revealed a strong increase of this D-amino acid, compared to 
respective wild-type littermates, while no difference between genotypes was found in 
the content of bicarboxylic L-amino acids, L-Asp (Errico et al., 2006; Huang et al., 
2006) and L-Glu (Huang et al., 2006). A more detailed neurochemical evaluation in 
specific brain regions of Ddo-/- mice, like the hippocampus, caudate putamen, cortex, 
cerebellum and olfactory bulbs, has confirmed that D-Asp increases approximately 10- 
to 20-fold, in relation to the corresponding wild-type brain areas (Errico et al., 2008b; 
Errico et al., 2008a; Errico et al., 2011c). Interestingly, as a direct consequence of D-
Asp increase, Ddo-/- brains also display higher content of endogenous NMDA (Errico 
et al., 2006; Errico et al., 2011c), the N-methyl derivative of D-Asp.  
Besides Ddo gene targeting, an alternative approach has been developed to increase 
D-Asp levels, based on 1- or 2-months-oral administration of D-Asp delivered in drink 
water to C57BL/6 mice. In this mouse model, HPLC detection has revealed a 
significant increase of D-Asp levels in the brain, even though to a lesser extent than in 
Ddo-/- animals due to the presence of DDO enzyme. Indeed, depending on the brain 
region examined and on the schedule of D-Asp administration, the endogenous levels 
of D-Asp in the hippocampus, cortex, caudate putamen and cerebellum of treated 
animals increase approximately from 2- to 5-fold, compared to the same brain areas of 
untreated mice (Errico et al., 2008b; Errico et al., 2008a; Errico et al., 2011b). 
 
1.8 Influence of increased D-aspartate levels on striatal synaptic plasticity and 
sensorimotor gating. 
Evaluation of electrophysiological properties of D-Asp in the caudate putamen 
indicates that local applications of this D-amino acid induce dose-dependent inward 
currents that, similarly to the hippocampus, are antagonized by the NMDAR blockers 
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MK801 and D-AP5 (Errico et al., 2008a). The effect of D-Asp on striatal glutamatergic 
transmission has been also extensively studied in Ddo-/- and D-Asp-treated mice. 
Electrophysiological data indicate that the excess of D-Asp is able to completely 
abolish corticostriatal long-term depression (LTD) (Errico et al., 2008a) and 
depotentiation (Errico et al., 2011c). Given the ability of D-Asp to activate striatal 
NMDARs, it is likely that the absence of corticostriatal LTD, in conditions of 
enhanced levels of D-Asp, may depend on the facilitatory effect of this D-amino acid 
on NMDAR-dependent transmission (Calabresi et al., 1992; Centonze et al., 2007). 
The effect of increased D-Asp on striatal LTD deserves a special remark if we consider 
that similar synaptic adaptations occur after chronic treatment with the typical 
antipsychotic haloperidol (Centonze et al., 2004). Moreover, in vivo experiments of 
acoustic startle response and prepulse inhibition (PPI), a test used to evaluate 
schizophrenia-like behaviour, indicate that chronic exposure to higher D-Asp levels 
does not affect basal properties of sensorimotor filtering but significantly attenuates 
the psychotic-like deficits induced in mice by the treatment with the psychotomimetic 
drugs amphetamine and MK801 (Errico et al., 2008a). Altogether, these data suggest 
a potential beneficial effect of D-Asp on sensorimotor filtering abilities. 
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2. Aim of the research 
Increasing evidence points to a role for dysfunctional glutamate N-methyl-D-
aspartate receptor (NMDAR) neurotransmission in schizophrenia. Accordingly, 
compounds that inhibit the glycine-1 transporter or target the glycine-binding site of 
NMDARs, including the co-agonists D-serine and glycine, have shown promise in 
treating the symptoms of schizophrenia. Together with D-serine, another D-form 
amino acid, D-Asp, exists in the brain of mammals. Synthesised by the enzyme 
aspartate racemase, D-Asp is highly concentrated in the prenatal brain; after birth, its 
levels sharply decrease due to the catabolising activity of the enzyme D-aspartate 
oxidase. D-Asp is able to stimulate NMDAR-dependent neurotransmission through 
direct action at the glutamate-binding site of NMDARs, thus functioning as an 
endogenous agonist for this subclass of glutamate receptors. The agonistic activity 
exerted by D-Asp on NMDARs and its neurodevelopmental occurrence make this D-
amino acid a potential mediator for some of the NMDAR-related alterations observed 
in schizophrenia. Therefore, aim of the research is to investigate about the potential 
role of D-Asp in schizophrenia-relevant circuits and behaviors. 
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3. Results 
3.1 D-aspartate levels in the post-mortem prefrontal cortex and caudate putamen 
of schizophrenia patients 
As indicated above, an increasing number of evidence shows that D-Asp 
activates NMDAR-dependent transmission (Errico et al., 2008b; Errico et al., 2008a; 
Errico et al., 2011c; Errico et al., 2011b; Errico et al., 2011a), whose deregulation has 
been implicated in the pathophysiology of SCZ (Javitt, 1987; Goff and Coyle, 2001; 
Sawa and Snyder, 2003; Coyle, 2012; Javitt, 2012). Therefore, we measured the levels 
of D-Asp in two brain areas known to be involved in the pathophysiology of this 
illness, such as the prefrontal cortex and the caudate putamen (Tan et al., 2007; Howes 
and Kapur, 2009) of post-mortem SCZ patients. To this aim, we have used high-
performance liquid chromatography (HPLC), based on the diastereomeric 
derivatization. In brief, amino acids contained in the biological matrix were derivatized 
to pairs of diastereomers with o-phthalaldehyde (OPA) and an optically active thiol 
reagent [N-acetyl-L-cysteine (NAC) that make them fluorescent. Then, the 
diastereomers were separated on non-chiral stationary phases, such as octadecylsilyl 
silica gel (ODS)-C18 column and finally detected fluorometrically at the proper 
wavelength. Interestingly, we have founded a consistent decrease of D-Asp levels both 
in the prefrontal cortex [Ctrl vs. SCZ (mean±SEM): 77.14±7.08 nmol/g tissue vs. 
44.10±2.62 nmol/g tissue, 43% reduction, p=0.0002, one-way ANOVA; Fig. 3.1a] and 
caudate putamen [Ctrl vs. SCZ (mean±SEM): 104.14±12.59 nmol/g tissue vs. 
61.80±4.30 nmol/g tissue, 41% reduction, p=0.002, one-way ANOVA; Fig. 3.1e] of 
SCZ patients compared with control individuals. Consistent with this strong reduction 
in D-Asp content, also the amount of its N-methyl derivative, NMDA, is reduced in 
the two brain areas of SCZ subjects analyzed [Ctrl vs. SCZ (mean ± SEM): prefrontal 
cortex, 5.26 ± 0.36 nmol/g tissue vs. 2.77 ± 0.18 nmol/g tissue, 47% reduction; caudate 
putamen, 9.79 ± 1.56 nmol/g tissue vs. 3.22 ± 0.34 nmol/g tissue, 67% reduction; p < 
0.01, per each brain area, Mann-Whitney test; Figure 3.1b and 3.1f]. Variation in D-
Asp levels can depend on the change in the levels of its precursor, L-Asp. However, 
our analysis display comparable levels of this L-amino-acid between controls and SCZ 
individuals in both areas analysed [Ctrl vs SCZ (mean ± SEM): prefrontal cortex, 4.69 
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± 0.20 μmol/g tissue vs 4.25 ± 0.13 μmol/g tissue; caudate putamen, 5.22 ± 0.14 
μmol/g tissue vs 4.82 ± 0.18 μmol/g tissue; p > 0.05, per each brain area, Mann-
Whitney test; Figure 3.1c and g]. Finally, we examined the levels of the principal 
agonist of NMDARs, L-Glu. While L-Glu levels in the prefrontal cortex did not vary 
significantly between the two diagnostic groups [Ctrl vs SCZ (mean ± SEM): 8.75 ± 
0.20 μmol/g tissue vs 8.63 ± 0.13 μmol/g tissue, p > 0.05, Mann-Whitney test; Figure 
3.1d], in the caudate putamen we found a slight reduction of this amino acid in SCZ 
samples, compared to controls [Ctrl vs SCZ (mean ± SEM): 11.04 ± 0.47 μmol/g tissue 
vs 9.76 ± 0.25 μmol/g tissue, 12% reduction; p < 0.05, Mann-Whitney test; Figure 
3.1h]. 
 
 
Figure 3.1: Detection of amino acids in the post-mortem brain samples of schizophrenia patients. 
The amino acids (a, e) D-aspartate (D-Asp), (b, f) N-methyl D-aspartate (NMDA), (c, g) L-
aspartate (L-Asp) and (d, h) L-glutamate (L-Glu) were measured by HPLC in the prefrontal cortex 
(a-d) and caudate putamen (e-h) of control (Ctrl, n = 7) and schizophrenia subjects (SCZ, n = 10). 
* p < 0.05, ** p < 0.01, *** p < 0.0001, compared to control group (Mann-Whitney test). Values 
are expressed as mean ± SEM. 
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3.2 Expression of NMDAR subunits are selectively reduced in the post-mortem 
prefrontal cortex of schizophrenia patients. 
 
In order to evaluate whether a constitutive deregulation of D-Asp levels may 
correlate with the expression of L-Glu receptors, we detected the levels of NMDAR 
subunits in the brain of SCZ patients. Interestingly, western blotting analysis displayed 
a significant decrease of GluN1 [p = 0.0100, Mann-Whitney test], GluN2A [p = 
0.0238, Mann-Whitney test] and GluN2B [p = 0.0242, Mann-Whitney test] subunits 
in the prefrontal cortex of SCZ patients compared to controls (Figure 3.2 top panel). 
Conversely, in the caudate putamen the protein levels of each of the NMDAR subunits 
analyzed are comparable between SCZ and controls patients [p > 0.1, per each protein, 
Mann-Whitney test; Figure 3.2 bottom panel]. The present data is in line with the 
hypothesis of a reduced glutamatergic function in SCZ and, notably, with a substantial 
involvement of a cortical alteration of NMDAR-dependent neurotransmission. 
 
 
Figure 3.2: Expression of NMDAR subunits in the post-mortem brain samples of schizophrenia 
patients. Expression of the subunits GluN1, GluN2A and GluN2B of the NMDAR was evaluated by 
western blotting in the post-mortem prefrontal cortex and caudate putamen of control individuals (Ctrl) 
and schizophrenia patients (SCZ). GAPDH protein was used to normalize variations in loading and 
transfer. Representative blots comparing the two diagnostic groups are shown for each protein detected 
and brain region analyzed. * p < 0.05, compared to control group (Mann-Whitney test). Values are 
expressed as mean ± SEM. 
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3.3 DDO mRNA expression and methylation of the DDO gene in the post mortem 
SCZ brain 
Variation in the mRNA content can depend on changes in the methylation 
degree within the regulatory regions of the corresponding gene. Therefore, we assessed 
whether the increase in DDO mRNA levels found in the PFC of SCZ patients could 
be associated with potential methylation changes in the CpG sites surrounding the 
ATG transcription start codon of the DDO gene. Our results showed that the pattern 
of methylation was unchanged in the PFC of patients, compared with control subjects 
[P>0.05 per each CpG site, analysis of covariance with covariance for post mortem 
delay, Figure 3.3b]. Therefore, the increase in DDO mRNA is not directly associated 
with methylation of the putative promoter region of the DDO gene. 
  
 
Figure 3.3: DDO mRNA expression and methylation of the DDO gene in the postmortem schizophrenia 
(SCZ) brain. (a) Analysis of DDO mRNA expression was performed by quantitative reverse 
transcription (qRT)-PCR in the PFC of SCZ patients and control individuals (Ctrl). Quantity means of 
transcript were normalized to the geometric mean of three housekeeping genes. (b) DDO gene 
methylation analysis by NGS. The top panel shows the structure of the putative promoter of human 
DDO gene. The transcriptional start site (+1) is indicated by an arrow. The putative regulatory upstream 
region (white box), exon (black) and first intron (striped box) are indicated. The primer positions used 
for methylation analysis are indicated by arrows (DDO Fw and DDO Rv). Vertical bars represent the 
relative positions of each CpG site. Black circles represent the CpG sites analyzed 
(CpG−194,−177,−142,−101,−8, +128 and +133). The bar graph below shows the methylation degree 
of single CpG sites at DDO promoter in the PFC of SCZ patients (gray bars) and Ctrl subjects (black 
bars) at each CpG site. **P<0.01, ANCOVA. All the values are expressed as mean±s.e.m.  
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3.4 LC/MSMS in Ddo-/- 
Results obtained in SCZ patients provide a stimulating hint for suggesting a 
potential role of D-Asp in the pathophysiology of this psychiatric illness. Therefore, 
we moved from human to mouse model with high levels of D-Asp (Errico et al., 2006; 
Errico et al., 2008a; Errico et al., 2011b) to evaluate the effect of deregulated levels of 
this molecule in NMDAR-dependent function and SCZ-like phenotype. For this 
purpose, we have developed a simple and rapid method for the simultaneous direct 
measurement of D-Asp, L-Asp and NMDA in brain tissue based on chiral fractionation 
of enantiamers and tandem mass spectrometry in multiple reaction monitoring (MRM) 
mode avoiding any derivatization step and with greater sensitivity than HPLC 
previously used. The MRM method allowed us to discriminate the target metabolites 
within the very complex mixture originated from tissue extracts. Briefly, D-Asp, L-
Asp and NMDA were directly resolved by HPLC on a Chirobiotic chiral stationary 
phases consisting of the amphoteric glycopeptide Teicoplanin covalently bound to 
silica gel and all three compounds could be unambiguously identified by their specific 
MRM transitions. All the analytical parameters, LOD, LOQ and LLOQ were 
determined. In Figure 3.4 are showed representative chromatogram obtained in our 
detection. In the first two panel are represented the chromatograms of standard solution 
of L-Asp (Figure 3.4a) or a mixture of L and D-Asp (Figure 3.4b), in order to evaluate 
the retention time of this amino acids and to confirm that this method is able to 
discriminate D- and L-form. Moreover, several tests were performed using mouse 
brain tissues as source of metabolites to evaluate the performances of the procedure in 
the presence of the matrix (Figure 3.4c). First, the concentration of L-Asp was 
determined in adult mouse brain samples showing clear detection of the metabolite 
and the complete absence of D-Asp, as expected. Neither interferences nor carryover 
peaks were observed in the MRM analysis. Then, different amounts of D-Asp (Figure 
3.4d), L-Asp or NMDA were spiked in mouse brain extracts and the recovery of the 
target metabolites was estimated always displaying values better than 90% for each 
analyte.  
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Figure 3.4: Representative LC-MS/MS chromatograms. (a) standard L-Asp solutions; (b) standard 
mixture of D- and L-Asp; (c) mouse brain extract; (d) mouse brain extract + spike of D-Asp. 
 
Finally, the developed procedure was applied to the quantitative determination 
of D-Asp and L-Asp in many brain samples from mouse models, and the results were 
compared with the same measurements carried out by HPLC. For the measurements 
we used mice with target deletion of Ddo gene (named Ddo knockout, Ddo-/-) and their 
relative controls (named Ddo wild type, Ddo+/+). Comparing HPLC and LC-MS/MS 
in MRM results, we showed that the absolute amount of D-Asp levels were different 
[HPLC: Ddo-/- 1384,446 nmol/g; Ddo+/+ 45,048 nmol/g; LC-MS/MS: Ddo-/- 5148,443 
nmol/g ; Ddo+/+ 259,420 nmol/g], but D/L ratio is approximately the same [HPLC: 
Ddo-/- 0,624; Ddo+/+ 0,019; LC-MS/MS: Ddo-/- 0,441; Ddo+/+ 0,012] (Figure 3.5).  
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Figure 3.5: D-Asp detection in the PFC: comparison between HPLC and LC-MS/MS. (a) schematic 
representation of PFC; (b) representative LC-MS/MS chromatogram of D- and L-Asp detection in Ddo-
/- PFC (c,e) D-Asp detection and (d,f) D/L ratio in the PFC obtained by (c,d) HPLC; (e,f) LC-MS/MS. 
 
Notably, we confirmed that target deletion of Ddo gene results in increased levels of 
D-Asp in different mouse brain area [PFC: p=0,0038; Hippocampus: p=0,0376; 
Cerebellum: p=0,0003, Student t test] (Fig. 3.5 and 3.6), while no difference was found 
in L-Asp content [p>0,05 in all brain area; Student t test] (Fig.3.6). 
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Figure 3.6: LC-MS/MS detection in the hippocampus and cerebellum of Ddo+/+ and Ddo-/- mice. (a) 
schematic representation of mouse hippocampus; (b) D-Asp and (c) L-Asp detection in the 
hippocampus; (d) Graphic display of cerebellum (e) D-Asp and (f) L-Asp levels in the cerebellum. 
 
The simultaneous, sensitive, fast, and reproducible measurement of these metabolites 
enabled us to correlate the amount of D-Asp with relevant pathophysiological 
processes.  
 
3.5 Dendritic morphology in mice with high levels of D-Aspartate 
Dendrite morphogenesis is a complex but well-orchestrated process and 
includes the development of dendritic branches, forming characteristic dendrite arbors, 
and dendritic spines, allowing neurons to communicate with each other. Emerging 
evidence reveals  that dendritic spine and dendrite arbor stability have crucial roles in 
the correct  functioning of the adult brain and that loss of stability is associated with 
psychiatric  disorders and neurodegenerative diseases (Kulkarni and Firestein, 2012). 
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Particularly, reductions in dendritic arbor size and spine number have been reported in 
individuals with schizophrenia (Glantz and Lewis, 2000).  
NMDA receptor signaling appears to have a major role in dendritic growth and the 
formation of new synapses (Lamprecht and LeDoux, 2004; Collingridge et al., 2013). 
Therefore, considering the ability of D-Asp to activate this type of Glu receptor, we 
investigated the effect of increased levels of D-Asp on neuronal morphology by Golgi-
Cox analysis. After 1-month-chronic treatment with D-Asp, pyramidal neurons of the 
PFC exhibited significantly increased dendritic length, compared with untreated 
animals [H2O vs D-Asp (mean ± s.e.m.): 1564.33 ± 62.16μm vs 2068.94 ± 
49.13μm,P<0.01; Figure 3.7a]. This morphological phenotype is also accompanied by 
greater complexity of dendritic tree between 25 and 125μm in basal dendritic segments 
[P<0.01 at 25, 50, 75 and 100μm; P<0.05 at 125μm] and 200 and 250μm in apical 
dendritic segments [P<0.05] (Figure 3.7b). Moreover, in this region we found 
increased spine density in D-Asp treated mice compared to controls [H2O vs D-Asp 
(mean ± s.e.m.): 3.03 ± 0.25 spines per 10μm vs 4.01 ± 0.25 spines per 10μm,P<0.05; 
Figure 3.7c]. 
Next, we examined dendritic architecture of pyramidal neurons in the CA1 area of the 
hippocampus of D-Asp-treated mice. As in the PFC, also in this brain region we found 
a significant extension in the length of the dendrites [H2O vs D-Asp (mean ± s.e.m.): 
1925.80 ± 98.97μm vs 2352.93 ± 126.97μm, P<0.05; Figure 3.7d] and increased spine 
density [H2O vs D-Asp (mean ± s.e.m.): 4.74 ± 0.25 spines per 10μm vs 5.78 ± 0.33 
spines per 10μm,P<0.05; Figure 3.7f] in treated animals, compared with controls 
(Figure 3.7e). 
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Figure 3.7: Analysis of dendritic morphology was performed on C57BL/6J mice drinking D-Asp or 
H2O in pyramidal neurons of the (a–c) PFC and (d–f) CA1subfield of the hippocampus after Golgi-Cox 
staining. (a and d) Total dendritic length (in μm) measured in the (a) PFC and (d) CA1 subfield of the 
hippocampus. (b and e) Number of intersections between basal or apical dendrites and Sholl concentric 
circle lines at different distances from soma center in both (b) PFC and (e) CA1 area. Concentric circles 
increase in diameter by 25μm increments. (c and f) Spine density (number of spines per 10μm) evaluated 
in (c) the PFC and (f) CA1 area of mice. The right panels show representative dendrites. **P<0.01, 
*P<0.05, compared with untreated mice (Student’st-test). ##P<0.01, #P<0.05, compared with untreated 
mice (Fisher’spost hoc). Scale bar, 5μm. 
To confirm the capability of D-Asp to influence the neuronal morphology, we also 
used knockout mice for Ddo gene. Similar to chronic treatment with D-Asp, we found 
increased total dendritic length in Ddo-/- mice compared to control littermates both in 
the PFC [Ddo+/+ vs Ddo−/− (mean ± s.e.m.): 1189.37 ± 28.63μm vs 1537.47 ± 
138.10μm,P<0.05; Figure 3.8a] and CA1 area of the hippocampus [Ddo+/+ vs Ddo−/− 
(mean ± s.e.m.): 1765.25 ± 117.58μm vs 2219.51 ± 43.86μm,P<0.01; Figure 3.8d]. 
Sholl analysis revealed no difference in the complexity of basal and apical dendrites 
in the PFC (Figure 3.8b).  On the other hand, in the CA1 area we found a greater 
number of intersections in the basal dendrites of  Ddo−/− mice between 50 and 125μm, 
compared with controls [P<0.01 at 50μm;P<0.05 at 75, 100 and 125μm, Figure 3.8e]. 
At last, dendrites from Ddo−/− neurons have greater spine density compared with 
control neurons in both areas analyzed [PFC: Ddo+/+ vs Ddo−/− (mean ± s.e.m.): 2.12 
± 0.09 spines per 10μmvs 2.76 ± 0.24 spines per 10μm,P<0.05; Figure 3.8c; 
Hippocampus: Ddo+/+ vs Ddo−/− (mean ± s.e.m.): 3.99 ± 0.16 spines per 10μm vs 4.53 
± 0.13 spines per 10μm, P<0.05; Figure 3.8f]. 
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Figure 3.8: Analysis of dendritic morphology was performed on Ddo+/+ and Ddo-/- mice in pyramidal 
neurons of the (a–c) PFC and (d–f) CA1subfield of the hippocampus after Golgi-Cox staining. (a and 
d) Total dendritic length (in μm) measured in the (a) PFC and (d) CA1 subfield of the hippocampus. (b 
and e) Number of intersections between basal or apical dendrites and Sholl concentric circle lines at 
different distances from soma center in both (b) PFC and (e) CA1 area. Concentric circles increase in 
diameter by 25μm increments. (c and f) Spine density (number of spines per 10μm) evaluated in (c) the 
PFC and (f) CA1 area of mice. The right panels show representative dendrites. **P<0.01, *P<0.05, 
compared with Ddo+/+ mice (Student’st-test). ##P<0.01, #P<0.05, compared with Ddo+/+ mice 
(Fisher’spost hoc). Scale bar, 5μm. 
 
3.6 High levels of D-Asp converts E-LTP into L-LTP in the adult hippocampus 
Dendritic spine density is strictly correlated with functional synaptic plasticity 
(Matsuzaki et al., 2004; Okamoto et al., 2004), in particular with long-lasting forms of 
synaptic potentiation, in which NMDARs are known to play a major role (ref). Given 
the ability of D-Asp to induce dendritic structural modifications and enhance early-
phase LTP (refs), we evaluated whether this D-amino acid was also able to affect late-
phase synaptic plasticity in the mouse hippocampus. As expected, using an early-phase 
LTP (E-LTP) induction paradigm (100 Hz, 1 s), we observed a decaying LTP in mice 
drinking water and in wild-type slices after 1 h. Strikingly, this protocol was sufficient 
to induce stablelate-phase (L-LTP) both in D-Asp-treated [LTP at 160 min, H2O = 16 
± 7%; D-Asp = 57 ± 7%;t-test, last 10 min of recording, P<0.001; Figure 3.9a] and 
Ddo-/- mice [LTP at 160 min, Ddo+/+  = 14 ± 5%, Ddo-/-  = 36 ± 5%; t-test, last 10 min 
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of recording, P<0.001; Figure 3.9d]. To investigate the nature of lowered threshold for 
the induction of L-LTP in presence of higher levels of D-Asp, we administered 
rapamycin before the conditioning train. In fact it is known that long lasting form of 
LTP is sensitive to this compounds (Tang et al., 2002; Costa-Mattioli et al., 2009). 
Notably, also in this condition L-LTP still persisted  in both mouse models [D-Asp 
treated: LTP at 160 min, vehicle = 57 ± 7%, rapamycin = 53 ± 4%; t-test, last 10 min 
of recording,P>0.05; Figure 3.9b; Ddo-/- : LTP at 160 min, vehicle = 36 ± 5%, 
rapamycin = 28 ± 5%; t-test, last 10 min of recording, P>0.05; Figure 3.9e]. It has been 
demonstrated that cytoskeletal stability is crucial for maintaining long-lasting forms 
of LTP (Huang et al., 2013). Interestingly, treatment with cytochalasin D, an actin 
polymerization inhibitor, fully prevented L-LTP in D-Asp treated [LTP at 160 min, 
vehicle = 57 ± 7%, cytochalasin D = 4 ± 5%;t-test, last 10 min of recording, P<0.001; 
Figure 3.9c] and Ddo-/- mice [LTP at 160 min, vehicle = 36 ± 5%, cytochalasin D = 5 
± 8%;t-test, last 10 min of recording, P<0.001; Figure 3.9f]. 
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Figure 3.9: Late-phase LTP in D-Asp-treated and Ddo-/- mice. Time plot of hippocampal fEPSP 
responses showing the effect of E-LTP stimulation paradigm in (a) untreated C57BL/6J mice and D-
Asp-treated C57BL/6J mice and (d) Ddo+/+ and Ddo-/- mice . Hippocampal L-LTP in (b) D-Asp-treated 
and (e) Ddo-/- mice was unaffected following bath-application of 20 nM rapamycin (transiently bath-
applied for 40 min) but was fully blocked following bath-application of 100 nM cytochalasin D 
(continuously bath-applied) as showed in the panels (c) and (f). Insets show field EPSPs from 
representative experiments during baseline and following LTP induction (1 s, 100 Hz tetanus). Vertical 
bar, 0.5 mV; horizontal bar, 10 ms.  
 
3.7 Increased levels of D-Asp affect schizophrenia-like behavior induced by PCP 
in mice.  
We then evaluated the effect of deregulated high levels of D-Asp on SCZ-like 
behaviors. To this aim we challenged Ddo−/− animals with phencyclidine (PCP). This 
drug mirrors the symptomatology of SCZ in humans (Domino, 1964; Allen and 
Young, 1978), primates and rodents (Morris et al., 2005; Jones et al., 2011; Javitt et 
al., 2012; Moghaddam and Krystal, 2012) by blocking NMDARs. First, we evaluated 
PCP-induced hyper-locomotion at two different doses, 3 and 6 mg/kg (Figure 3.10). 
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As expected, this drug caused increasing motor hyperactivity in Ddo+/+ mice at the two 
doses analyzed (Figure 3.10). In Ddo-/- mice, 3 mg/kg PCP produced locomotor 
stimulation similar to that evoked in Ddo+/+ animals [three-way ANOVA with repeated 
measures: treatment × genotype, F(1,240) = 0.173, P= 0.6789]. Interestingly, at the dose 
of 6 mg/kg, Ddo-/- animals show attenuated motor hyperactivity compared to wild-type 
littermates [two-way ANOVA with repeated measures: genotype effect, F(1,120) = 
6.952,P= 0.0145] (Figure 3.10).  
 
Figure 3.10: Motor activity induced by 3 mg/kg or 6 mg/kg PCP in Ddo+/+ and Ddo−/− mice. Locomotion 
was expressed as distance traveled, measured in cm every 10 min over a 60-min session  and presented 
as time course. 
Next, using a Prepulse Inhibition (PPI) paradigm, we investigate the effect of PCP on 
sensorimotor gating of Ddo-/- mice (figure 3.11). PPI is a paradigm commonly used to 
evaluate SCZ-like symptoms both in animal models and in humans. This test evaluates 
the integrity of sensorimotor gating, a function often destroyed in SCZ patients. As 
expected, PCP at the dose of 3 mg/kg significantly destroyed PPI in Ddo+/+ animals 
[two-way ANOVA with repeated measures: treatment effect, F(1,54) = 4.906, P= 
0.0399; Figure 3.11a]. Conversely, in Ddo-/- 3mg/kg PCP does not produce any effect 
on sensorimotor gating, as revealed by a comparable startle amplitude between treated 
and vehicle-treated mice [F(1,54)= 1.668, P= 0.2129; Figure 3.11a]. Conversely, the 
dose of 6 mg/kg PCP caused PPI deficits in both Ddo+/+ and Ddo-/- mice [treatment 
effect: Ddo+/+, F(1,54) = 6.919, P= 0.0170; Ddo
−/−, F(1,54) = 6.343,P= 0.0215; Figure 
3.11b].  
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Figure 3.11: PPI deficits induced by (a) 3 mg/kg or (b) 6 mg/kg PCP in Ddo+/+ and Ddo−/− mice. 
Percentage of the PPI was used as dependent variable and measured at different prepulse intensities (dB 
above 65 dB background level). *P<0.05, compared with vehicle control groups. All the values are 
expressed as the mean±s.e.m.  
 
Taken together, these results point to a reduced reactivity to PCP-induced 
psychotomimetic behaviors in Ddo−/− animals, compared to wild-type littermates.  
To evaluate whether increased D-Asp levels are always able to protect against 
sensorimotor deficits produced by PCP or, rather, it is important the time-window in 
which D-Asp content increases, we repeated PPI experiments in C57BL/6 mice 
chronically treated with D-Asp for 1 month (20 mM in tap water), during adulthood. 
At the dose of 3 mg/kg, pretreatment with D-Asp did not significantly alter the PPI 
deficits induced by PCP [D-Asp pretreatment effect: F(1,99)= 2.386, P= 0.1320; D-Asp 
pretreatment × PCP treatment: F(1,99)= 0.026, P= 0.8726; Figure 3.12a]. We found 
similar results after 6 mg/kg PCP treatment [D-Asp pretreatment effect: F(1,102)= 0.732, 
P= 0.3983;D-Asp pretreatment × PCP treatment: F(1,102) = 0.017, P= 0.8960; Figure 
3.12b]. 
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Figure 3.12: Prepulse inhibition responses to PCP after 1-month oral administration of D-Asp in mice 
treated with (a) 3 mg/kg PCP or vehicle, (b) 6 mg/kg PCP or vehicle. Percentage of the PPI was used 
as dependent variable and measured at different prepulse intensities (shown as dB above 65 dB 
background level). All the values are expressed as the mean±s.e.m.  
3.8 fMRI response induced by PCP  
Considering the ability of D-Asp to influence NMDAR activity and PCP-
induced behaviors, we evaluated if increased levels of this D-amino acid can modulate 
the aberrant neuro-functional cascade underlying the psychotomimetic effect of PCP. 
To this purpose, we used fMRI to map the neural substrates recruited by a 
subanesthetic dose of PCP (intravenous, 1 mg/kg). Consistent with rodent and human 
imaging studies (Gozzi et al., 2008b; Bifone and Gozzi, 2012; De Simoni et al., 2013; 
Doyle et al., 2013), control mice showed a robust cortico–limbo–thalamic fMRI 
response to the drug, with a prominent involvement of the prefrontal–orbitofrontal, 
cingulate and visual cortex, ventral hippocampus and mediodorsal thalamic nuclei 
(Figures 3.13a). By contrast, a generalized attenuation of PCP-induced fMRI response 
was observed in Ddo−/− mice, with respect to wild-type animals (Figures 3.13b). 
Quantification of the effect in representative volume of interest revealed a statistically 
significant attenuation in several brain regions, including prefrontal, orbitofrontal 
anterior and posterior (retrosplenial) cingulate, visual and parietal cortex and ventral 
hippocampus [P>0.05 in all regions, Student’st-test; Figure 3.13c,d]. Overall, these 
results suggest that a challenge with PCP in Ddo−/− animals is associated with 
consistent alterations of blood flow in brain areas known to be involved in the 
pathophysiology of SCZ.  
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Figure 3.13: PCP-induced fMRI response in Ddo−/− mice. (a and c) In Ddo+/+ mice, PCP elicited robust 
and sustained cortico–limbo–thalamic fMRI activation. (b–d) This effect was strongly attenuated in  
Ddo−/− mice. Red/yellow in a and b indicates significant fMRI (rCBV) response to PCP (1 mg/kg, intra-
artery) with respect to vehicle (saline; 3.1<z-score<6, cluster correction threshold pc=0.001). *P<0.05, 
Student’st-test. Cg, cingulate cortex; dCPU, dorsal caudate putamen; fMRI, functional magnetic 
resonance imaging; mPFC, medial prefrontal cortex; OFC, orbitofrontal cortex; PCP, phencyclidine; 
rCBV, relative cerebral blood volume; Rs, retrosplenial cortex; Th, thalamus; vHc, ventral 
hippocampus; V1, visual cortex. 
As in the case of PPI experiments, we then assessed the fMRI response induced by 
PCP after 1-month chronic D-Asp administration. Both D-Asp- and H2O-treated mice 
exhibited a robust cortico–limbo–thalamic fMRI response to the drug, with a 
prominent involvement of the prefrontal–orbitofrontal, cingulate and visual cortex, 
ventral hippocampus and mediodorsal thalamic nuclei (Figures 3.14). However, no 
statistically significant inter-group difference in the response to PCP was observed 
either at the voxel level [z>1.6, cluster corrected at P<0.01) or when integrated at the 
level of volumes of interest (right panel; P>0.27, all regions, Student’s t-test]. Overall, 
in contrast to Ddo−/− mice, D-Asp supplementation failed to produce any significant 
modulation of PCP-induced PPI and fMRI responses. The lack of inhibitory effect 
observed suggests that D-Asp elevation in normally developed brains may not be 
sufficient to prevent SCZ-like hyperglutamatergic state, and points at a putative 
neurodevelopmental origin for some of the phenotypes observed in Ddo−/− mice. 
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Figure 3.14: PCP-induced fMRI response in D-Asp- and H2O-treated adult C57BL6/J mice. In both 
groups of animals, PCP elicited robust and sustained cortico–limbo–thalamic fMRI activation (a and b 
panels). No statistically significant difference in the inter-group response to PCP was observed either at 
the voxel level (z>1.6, cluster corrected at P<0.01) or when integrated at the level of volumes of interest 
(panel b; P>0.27, all regions, Student'st-test). Cg, cingulate cortex; dCPU, dorsal caudate putamen; 
fMRI, functional magnetic resonance imaging; mPFC, medial prefrontal cortex; OFC, orbitofrontal 
cortex; PCP, phencyclidine; rCBV, relative cerebral blood volume; Rs, retrosplenial cortex; Th, 
thalamus; vHc, ventral hippocampus; V1, visual cortex. 
 
3.9 Does D-Asp cross the blood brain barrier? 
In the light of the ability of exogenous D-Asp to influence NMDAR-mediated 
processes in the mouse brain, we investigated whether D-Asp can cross the blood brain 
barrier, a highly selective permeability barrier that separates the circulating blood from 
the brain extracellular fluid in the central nervous system. To this aim, we performed 
in vivo microdialysis experiments in the PFC of freely moving C57BL/6 mice treated 
with acute injection of 500 mg/kg D-Asp. Samples collected were analyzed for D-Asp 
and L-Asp content. Remarkably, this treatment caused a strong increase in 
extracellular D-Asp levels [two-way ANOVA with repeated measures, F(1,80) = 
287.840;  P<0.0001, Figure 3.15a] with a peak 40 min after injection [2430±170 nM, 
~240-fold increase over basal levels, Figure 3.15a]. Moreover, D-Asp administration 
also affected free L-Asp content [F(1,80)=8.011;  P=0.0221;  Fig.  3.15b], although the 
increase was smaller than that observed for D-Asp [230±10 nM, ~3-fold increase], and 
returned to baseline already 80 min after injection (Figure 3.15b). We also executed 
Analysis on PFC omogenates 2 h after D-Asp injection to evaluate if the changes in 
the extracellular levels of these amino acids mirror the total amount of these molecules. 
Results showed a strong increase of D-Asp in the PFC omogenate of D-Asp-treated 
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mice compared to vehicle-treated group [P=0.0289; Fig 3.15c], while no difference 
was found in L-Asp content [P=0.6809; Fig 3.15d]. 
  
Figure 3.15: D-Asp and L-Asp extracellular concentration after acute administration of the D-Asp. (a, 
b)  Time course of cortical extracellular concentration of free D-Asp and free L-Asp in control 
animals and in mice subjected to the acute i.p. administration of 500 mg/kg D-Asp. (c, d) Free D-Asp 
and free L-Asp total contents in PFC homogenates of control and acutely treated mice after 2 hours 
from treatment. The amount of D-Asp and L-Asp in tissue homogenates was normalized by the total 
protein content of each sample. The graphs displayed the mean values ± SEM; * P < 0.01 two-way 
ANOVA with repeated measures followed by Fisher’s post hoc test for microdialysis analyses and 
Student’s t test for homogenates analyses. 
 
 
3.10 D-Asp is released in a calcium-dependent manner 
We then performed in vivo microdialysis also on C57BL/6 mice treated for 1 
month with D-Asp to measure the concentration of this D-amino acid in the dialysates 
collected from the PFC. As shown in Figure 3.16a, D-Asp extracellular levels were 
significantly increased by the treatment, at each  time  point  analyzed  [two-way 
ANOVA with repeated measures F(1,32)=11.045, P=0.0105]. On the other hand, no 
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variation in the levels of the L-enantiomer was found between groups [two-way 
ANOVA with repeated measures F(1,32)=0.614, P=0.4558; Figure 3.16b]. Interestingly, 
by removing calcium from the ACSF in the last dialysate fraction, we observed that 
free D-Asp levels, as well as free L-Asp, became undetectable (Figure 3.16a,b), thus 
proving that the release of this amino acid is Ca2+-dependent. As reported after acute 
treatment, also in chronically treated mice we found a significant increase in D-Asp 
levels in the PFC homogenates, compared to controls [D-Asp vs. H2O: 2.76±0.27 
nmol/mg prot vs. 1.20±0.26 nmol/mg prot; P=0.0057, Student’s t-test; Figure3.16c]. 
Conversely, the amount of L-Asp did not change with the treatment [D-Asp vs. H2O: 
29.4±1.5 nmol/mg prot vs. 30.7±1.5 nmol/mg prot; P=0.5759; Figure 3.16d). 
 
Figure 3.16: D-Asp release in the PFC of freely moving mice. (a, b) Cortical extracellular concentration 
of free D-Asp and free L-Asp in control animals and in mice subjected to the chronic administration of 
20 mM D-Asp. (c, d) Free D-Asp and free L-Asp total contents in PFC homogenates of control and 
chronically treated mice. The amount of D-Asp and L-Asp in tissue homogenates was normalized by 
the total protein content of each sample. The graphs displayed the mean values±SEM; ** P<0.005 two-
way ANOVA with repeated measures followed by Fisher’s post hoc test for  microdialysis analyses and 
Student’s t-test for homogenates analyses. 
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3.11 D-Asp modulates L-Glutamate release in the mouse brain 
We have previously described the ability of D-Asp to modulate NMDAR-
dependent functions. Here, we investigated the consequences of elevated D-Asp 
content on the basal extracellular levels of L-Glu, the principal endogenous agonist of 
NMDARs. Interestingly, in vivo microdialysis performed in the hippocampus of adult 
Ddo-/- mice revealed an increase in L-Glu content, compared to Ddo+/+ counterpart 
[two-way ANOVA with repeated measures F(1,12)=14.87; P<0.01; Figure 3.17a]. The 
same analysis was carried out in the PFC of C57BL/6 mice treated with acute or 
chronic administration of D-Asp. Consistently, we observed a D-Asp-induced increase 
of L-Glu efflux both in acutely [two-way ANOVA with repeated measures 
F(1,40)=25.578, P=0.001; Figure 3.17b] and chronically treated animals [two-way  
ANOVA with repeated measures F(1,32)=34.454, P=0.0004; Fig. 3.17c], thus 
suggesting that D-Asp is able to produce the in vivo release of L-Glu. 
 
 
Figure 3.17: Increased D-Asp levels yields to a significant increase in the cortical extracellular levels 
of L-Glu. Cortical extracellular levels of L-Glu in (a) Ddo+/+ and Ddo-/- mice, (b) control animals and  
mice subjected to the acute administration of 500 mg/kg of D-Asp, or (c) to the chronic oral treatment 
with 20 mM D-Asp. The graphs displayed the mean values±SEM; Significance was analyzed using 
two-way ANOVA with repeated measures followed by Fisher’s post hoc test. 
To comprehend the mechanism through which D-Asp triggers L-Glu release from 
glutamatergic nerve terminals, we isolated synaptic terminals from cerebrocortical 
neurons, called synaptosomes. On this preparation continuously superfused with a 
medium containing the non-selective excitatory amino acid transporter (EAAT) 
inhibitor TBOA (10 µM), we tested the ability of D-Asp to evoke L-Glu release, in the 
presence of K+-induced depolarization. Spontaneous L-Glu levels were 21.3±1.1 nM 
(n=180), reported as zero in the graphic (Figure 3.18). A 90 s pulse with 15 mM K+ 
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caused a transient ~2.5-fold elevation of L-Glu levels over basal values, corresponding 
to a net release of 35.6±3.4 pmol/mg prot/min (Figure 3.18). D-Asp, L-Asp and 
NMDA (perfused at 10 µM) caused a similar ~3-fold elevation of the K+-evoked L-
Glu release [86.9±10.7, 112.1±12.4 and 106.9±15.4 pmol/mg prot/min, n=30, n=27, 
n=6, respectively; P<0.001; Figure 3.18a]. The effect of these agonists was differently 
sensitive towards subtype-selective L-Glu receptor antagonists (Figure 3.18). In fact, 
the non-competitive NMDAR antagonist MK-801 prevented the stimulation evoked 
by NMDA [treatment effect: F(2,15)=12.61, P=0.0006; NMDA vs. NMDA  + MK-801, 
P<0.01], attenuated that evoked by D-Asp [treatment effect: F(2,26)=6.32, P=0.0058; D-
Asp vs. D-Asp + MK-801, P<0.05] but left unchanged the response to L-Asp 
[treatment  effect: F(2,34)=6.97, P=0.0029; L-Asp vs. L-Asp + MK-801, P>0.05] 
(Figure 3.18a). Moreover, we treated synaptosomes with blockers of other Glu 
receptor as the ionotropic receptor AMPA and the metabotropic receptor mGluR5. 
Results showed that the AMPA receptor antagonist (CNQX) and mGluR5 antagonist 
(MTEP) prevented the effect of D-Asp [treatment effect:  F(3,56)=9.84, cerebrocortical  
P<0.0001; D-Asp vs.  D-Asp + CNQX or D-Asp + MTEP P<0.01] but left unchanged 
that of L-Asp [treatment effect: F(3,38)=10.23, P<0.0001; L-Asp vs. L-Asp + CNQX or 
L-Asp + MTEP P>0.05] (Figure 3.18b). Overall, this data revealed that D-Asp 
stimulates Glu release through presynaptic NMDA and non-NMDA ionotropic and 
metabotropic receptors.  
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Figure 3.18: D-Asp stimulates L-Glu release from cerebrocortical synaptosomes through presynaptic 
NMDA and non-NMDA receptors. (a, b)  Cerebrocortical synaptosomes were continuously perfused 
with a medium containing the EAAT inhibitor TBOA (10 µM), and stimulated with 15 mM K+ for 90 
sec. D-Asp, L-Asp and NMDA (10 µM) were added 3 min prior K+ and maintained for further 3 min. 
MK-801 (a), CNQX or MTEP (b) were added 3 min before agonists and maintained until the end of 
experiment. Data represent net extra release (i.e. release above baseline), and are expressed as 
mean±SEM pmol/mg prot/min. ** P <0.01 different from K+ alone, ° P <0.05, °° P <0.01 different from 
K+ in the presence of agonist (one-way ANOVA followed by the Newman-Keuls test for multiple 
comparisons). 
 
3.12 Effect of olanzapine on L-Glutamate, D-Aspartate and L-Aspartate 
extracellular levels 
Several evidence has proved that second-generation antipsychotics influence 
glutamatergic system (Bakshi and Geyer, 1995; Duncan et al., 1999; Goff et al., 2002; 
Carli et al., 2011). In this light, we tested the effect of olanzapine, an atypical 
antipsychotic, on Glu extracellular levels in the PFC. To this aim, we treated C57BL/6 
mice with i.p. injection of 5 mg/kg olanzapine for 4 weeks. Twenty-four hours after 
the last injection, we collected and analyzed dialysates using in vivo microdialysis 
approach. Interestingly, results showed a significant increase in L-Glu extracellular 
content in olanzapine-treated mice, compared to controls [two-way ANOVA with 
repeated measures, treatment effect: F(1,16)=52.596, P=0.0019; Figure 3.19a]. 
Considering that also D-Asp is able to increase the cortical release of L-Glu (Figure 
3.17), we examined whether olanzapine may influence extracellular content of D-Asp. 
Strikingly, chronic treatment with this antipsychotic drug caused a cortical increase of 
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extracellular free D-Asp [two-way ANOVA with repeated measures F(1,16)=210.177, 
P=0.0001; Figure 3.19b]. Remarkably, we also detected augmented levels of this D-
amino acid in total tissue extract of olanzapine-treated mice compared to untreated 
littermates [P=0.0064 Figure 3.19d]. Furthermore, our analysis revealed that chronic 
olanzapine administration also enhanced cortical extracellular L-Asp levels, although 
the increment was less than that of D-Asp [two-way ANOVA with repeated measures: 
F(1,16)=45.837; P=0.0025; Figure 3.19c]. Unlike the D-Asp, no difference was found 
in L-Asp total level [P=0.6419; Figure 3.19e]. 
 
Figure 3.19: Olanzapine chronic administration triggers L-Glu release in the PFC and increases D-Asp 
total content and release. Free (a) L-Glu, (b) D-Asp and (c) L-Asp extracellular concentration in control 
animals and in mice subjected to the chronic administration of 5 mg/kg Olanzapine. Free (d) D-Asp and 
free (e) L-Asp total concentration in control and olanzapine treated mice. The amount of D-Asp and L-
Asp in tissue homogenates was normalized by the total protein content of each sample. The graphs 
displayed the mean values ± SEM; ** P < 0.005 two-way ANOVA with repeated measures followed 
by Fisher’s post hoc test for microdialysis analyses and Student’s t-test for homogenates analyses.  
 
3.13 Effect of Olanzapine on DDO activity 
In the light of previously microdialysis results showing the ability of 
olanzapine to influence D-Asp levels in the homogenate fraction, we performed an 
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inhibition assay to assess if this antipsychotic drug could affect the activity of murine 
and human recombinant DDO (mDDO and hDDO, respectively). The assay was 
performed using different concentrations of antipsychotic (in the 0-300 μM range) at 
a fixed saturating concentration of exogenous FAD (100 μM). Interestingly, 
olanzapine was able to inhibit both mDDO and hDDO activity in a dose-dependent 
manner according to a classical sigmoidal dose-response curve (Figure 3.20a,b), with 
an IC50 value of 5.6±0.8 and 23.4±1.6 respectively. Notably, using a lower, 
physiological FAD concentration in the assay mixtures (4 μM), we observed a 4-fold 
increase in the inhibition efficiency of olanzapine on mDDO  [IC50=1.4±0.2 μM; 
Figure 3.20a], whereas the IC50 value of hDDO was not affected [IC50=23.1±3.2 μM, 
Figure 3.20b]. Conversely, if we performed the same experiment with clozapine, 
another atypical antipsychotic, DDO activity did not changed (Figure 3.20c,d). 
  
Figure 3.20: Olanzapine inhibits murine and human DDO activity. (a-d) Enzyme inhibition assays 
performed by using recombinant (a, c) mDDO or (b, d) hDDO and (a, b) olanzapine or (c,d) clozapine 
as inhibitors. DDO activity in the presence of different concentrations of the antipsychotics (in the 0-
300 µM range) and two FAD concentrations (4 and 100 μM) was determined by the Amplex UltraRed 
assay and an automated liquid handler system. The plots display the mean values ± STD deviation. The 
IC50 values represent the olanzapine concentration required for 50% inhibition of the enzymatic 
activity. 
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4. Conclusion 
D-Asp and D-Ser are the only two D-amino acids found in considerable amount 
in mammalian tissues, including the brain (Hashimoto and Oka, 1997). In the last 
years, intensive research has demonstrated that D-Ser is an endogenous co-activator at 
the strychnine-insensitive glycine site of NMDARs (Martineau et al., 2006; Billard, 
2012) and that its metabolism is altered in SCZ patients (Hashimoto et al., 2003; 
Hashimoto et al., 2005), supporting a role for this D-amino acid in psychiatric 
disorders. Also D-Asp is known to bind and activate NMDARs (Errico et al., 2012). 
Moreover, electrophysiological and behavioural studies on animal models with 
increased levels of D-Asp have revealed a contribution of D-Asp in the regulation of 
NMDAR-dependent synaptic activity and function (Errico et al., 2012). The NMDAR 
is a specific type of ionotropic Glu receptor and forms a heterotetramer between two 
GluN1 and two GluN2 subunits. This type of Glu receptors has been implicated in the 
pathophysiology of SCZ (Javitt, 1987; Goff and Coyle, 2001; Sawa and Snyder, 2003; 
Coyle, 2012; Javitt, 2012). Previous study, in line with hypo-glutamatergic hypothesis 
of SCZ, revealed variable changes in the expression patterns of NMDAR subunits in 
the dorsolateral prefrontal cortex, depending on the cohorts of SCZ patients analysed 
(Sokolov, 1998; Dracheva et al., 2001), while no changes  have been described in the 
caudate putamen (Dracheva et al., 2001). Therefore, we have analysed the expression 
of NMDAR subunits in post-mortem SCZ patients. Coherently, our experiments 
highlighted a significant decrease in GluN1, GluN2A and GluN2B in the prefrontal 
cortex but not in the caudate putamen of SCZ patients. Considering that D-Asp is able 
to modulate NMDAR function, along with the interest in potential therapies targeting 
D-amino acids in psychiatric disorders (refs), we evaluated the levels of D-Asp and its 
derivative, NMDA, in the post-mortem brains of SCZ patients. To this aim, we have 
used high-performance liquid chromatography (HPLC), based on the diastereomeric 
derivatization of samples. Interestingly, we found a consistent decrease in D-Asp 
levels, in both prefrontal cortex and caudate putamen of SCZ patients. Coherently, also 
its N-methyl-derivative, NMDA, is reduced in both regions analysed. The alteration 
of D-Asp levels does not depend by variation in the levels of its precursor, L-Asp, 
whose amount results unaltered. On the other hand, our neurochemical analysis 
revealed a mild but significant decrease in L-Glu content (12%) in the caudate 
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putamen, but not in the PFC of SCZ brains compared to healthy individuals. The 
reduction of D-Asp levels in SCZ samples correlates with increased expression of 
DDO gene, which encodes for the only enzyme known to catabolize D-Asp. In the 
absence of available antibodies selective for DDO, this evidence leaves us to 
hypothesize that the decreased levels of D-Asp in SCZ patients could be due to 
increased expression of the enzyme DDO. Finally, we revealed that alteration in DDO 
mRNA expression is not caused by epigenetic modifications in the methylation degree 
of CpG sites within the putative promoter of the DDO gene.  
Overall, the results obtained in SCZ patients suggest a potential involvement of D-Asp 
in the pathophysiology of this psychiatric illness. Nevertheless, the biological 
significance and the relative functional contribution of reduced levels of D-Asp and 
NMDA in SCZ  remain to be clarified. Therefore, we moved from humans to mouse 
models (Errico et al., 2006; Errico et al., 2008a; Errico et al., 2011b) to investigate 
whether non-physiological higher levels of D-Asp can affect SCZ-like phenotype and 
counteract SCZ-like behavioural and functional deficits induced by the 
psychotomimetic drug PCP. To this aim, we have developed a simple and rapid 
method for the simultaneous direct measurement of D-Asp, L-Asp and NMDA in brain 
tissue based on chiral fractionation of enantiamers and tandem mass spectrometry in 
multiple reaction monitoring (MRM) mode (LC-MS/MS). This method allowed us to 
detect D-Asp in the brain with greater sensitivity than HPLC previously used, and to 
correlate the amount of this D-amino acid with relevant pathophysiological processes. 
LC-MS/MS analysis confirmed what we have previously found by HPLC analysis 
(Errico et al., 2006; Errico et al., 2008a; Errico et al., 2011a), namely that the targeted 
deletion of the Ddo gene results in increased levels of D-Asp in the mouse brain, while 
no difference was found in L-Asp content. Analysis on mouse models with high levels 
of D-Asp revealed that the ability of this D-amino acid in activating the NMDA 
receptors is mirrored by increased dendritic arborization and spine density, and 
facilitated induction of late-phase LTP. Previous evidence indicates that storage of 
long-term memories is likely dependent on enhancement of long-term synaptic 
plasticity (Lamprecht R, LeDoux J. Structural plasticity and memory. Nat Rev 
Neurosci 2004; 5: 45–54). Thus, facilitation of L-LTP induced by higher levels of D-
Asp is coherent with the improvement of cognitive abilities previously found in D-
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Asp-treated and Ddo−/− mice (refs). Moreover, the block of L-LTP by cytochalasin D 
in mice with increased levels of D-Asp may suggest a potential effect of D-Asp on 
mTORC2 pathway since this complex is known to control actin polimerization and, in 
turn, the consolidation of long-term memories (Huang et al, Nat Neurosci, 2013).  
Remarkably, in serine racemase-deficient mice, reduction in D-Ser levels that results 
in NMDAR hypofunction, causes morphological defects, as well as alterations in 
mEPSCs and synaptic plasticity, paralleled by reduced mTOR signalling (Balu and 
Coyle, 2012; Balu et al., 2013). Several studies have linked altered metabolism of the 
endogenous NMDAR co-agonist D-Ser to the etiopathology of SCZ (Hashimoto et al., 
2003; Hashimoto et al., 2005; Yamada et al., 2005). The functional and structural 
similarities between D-Ser and D-Asp strengthen the hypothesis of a potential 
convergence of D-Asp on SCZ pathophysiology.  
To evaluate in a preclinical model the effect of an altered metabolism of D-Asp on 
SCZ-like manifestations, we tested psychotic-like effect of PCP in Ddo−/− mice. This 
drug induces SCZ-like psychotic effects by blocking NMDARs (Javitt, 1987; Javitt et 
al., 2012; Moghaddam and Krystal, 2012). We found significantly reduced 
psychostimulant effect of PCP in Ddo−/− mice, as shown by their attenuated motor 
hyperactivity, compared with control littermates. Most importantly, constitutively 
increased levels of D-Asp in knockout animals also produced a reduced sensitivity to 
PCP-dependent disruption of sensorimotor gating. As the PPI paradigm is used as an 
endophenotypic trait to assess dysfunction of sensorimotor gating processing in SCZ 
patients (Gottesman and Gould, 2003), the modulation of PCP-induced disruption of 
PPI in animals characterized by elevated D-Asp levels is of potential translational 
relevance. In line with behavioral data, fMRI results show that increased D-Asp, 
through its ability to promote NMDAR transmission, strongly inhibited the functional 
activation elicited by PCP in cortico–limbo–thalamic regions of Ddo−/− mice. This 
effect is consistent with previous imaging work showing that pharmacological 
potentiation of NMDAR function by D-Ser, can effectively inhibit the 
hyperglutamatergic state produced by NMDAR antagonism (Gozzi et al., 2008c) and 
modulate psychosis-related neurocircuits. Interestingly, oral supplementation of a 
neurobiologically active dose of D-Asp to adult C57BL/6 mice failed to inhibit PCP-
induced behavioral or functional responses. These findings point at a putative 
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neurodevelopmental origin for some of the phenotypes observed in Ddo−/− mice and 
suggests that both the time window and duration of increased D-Asp could have a 
critical role in shaping NMDAR-mediated circuit responsivity.  
To better understand how exogenous D-Asp influences NMDAR function and SCZ-
related phenotypes, we analysed the effects of D-Asp administration on the exogenous 
levels of this D-amino acid. First, we revealed that acute injection of D-Asp rapidly 
enhances the extracellular levels of free D-Asp in the PFC of freely moving mice, 
proving the evidence that exogenous D-Asp can efficiently cross the blood brain 
barrier. As after acute injection, we found that also chronic oral administration of D-
Asp is able to enhance  the  extracellular  levels  of  this  D-amino  acid  in  the  mouse  
PFC.  Furthermore, we demonstrated that this release occurs through a Ca2+-dependent 
process, since without Ca2+ the extracellular content of D-Asp becomes undetectable. 
Such result is in accordance to previous in vitro findings showing that D-Asp can be 
released through vesicular Ca2+-mediated exocytosis (Davies and Johnston, 1976; 
Malthe-Sorenssen et al., 1979; Wolosker et al., 2000; Nakatsuka et al., 2001; D'Aniello 
et al., 2010).  Remarkably, we found that both acute and chronic D-Asp treatment is 
able to increase the extracellular levels of L-Glu in freely moving mice. In this regard, 
using synaptosomal preparation from mouse PFC, we also revealed that D-Asp, but 
not L-Asp, stimulates presynaptic L-Glu release acting on NMDA, AMPA/kainate and 
mGluR5 receptors, suggesting that D-Asp could activate NMDAR both directly and 
indirectly by promoting Glu release.  
As D-Asp, also the second-generation antipsychotic olanzapine is able to affect 
glutamatergic system (refs). Interestingly, we have found that olanzapine is able to 
increase extracellular D-Asp levels in the PFC of treated mice due to its ability to 
inhibit DDO activity, as demonstrated by in vitro assays with both human and mouse 
recombinant enzymes. Altogether, our results highlight an unexpected role for 
olanzapine in the modulation of free D-Asp metabolism and lead us to hypothesize 
that the reported increase of the endogenous extracellular D-Asp may be one of the 
mechanisms by which this antipsychotic influences glutamatergic neurotransmission.  
Taken together, these findings support a role for D-Asp in phenotypes relevant to SCZ. 
Consistent with a neurodevelopmental hypothesis of SCZ (Fatemi and Folsom, 2009; 
Owen et al., 2011), a putative precocious down regulation of D-Asp levels, associated 
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to abnormal metabolism of this molecule, may have a much greater impact during 
critical phases of brain development, when D-Asp levels are physiologically high 
(Hashimoto et al., 1993; Sakai et al., 1998; Wolosker et al., 2000). Moreover, our 
results and previous evidence suggest that this D-amino acid, like D-Ser (Tsai et al., 
1998; Hashimoto et al., 2013; Balu and Coyle, 2015), may prove to be beneficial also 
in humans and could be potentially tested as an add-on to antipsychotics for 
schizophrenia treatment. Future studies in mouse models permitting controlled 
exposure of D-Asp levels during neurodevelopment will be made to investigate this 
basic issue.  
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5. Materials and Methods 
5.1 Tissue collection 
Prefrontal cortex and caudate putamen samples from post-mortem brains of 
non-psychiatrically ill individuals (controls) and subjects with SCZ were obtained 
from the brain bank of the Institute of Psychiatry, King’s College London, UK. All 
tissue collection and processing was carried out under the regulations and licences of 
the Human Tissue Authority and in accordance with the Human Tissue Act of 2004. 
Clinical diagnosis of SCZ was performed according to DSMIII-R criteria. 
Demographic characteristics of the control and SCZ subjects are described in Table 
5.1. The analyses of age, gender and post-mortem interval effects between the two 
groups are shown separately for each experiment in the next sections. 
 
Table 5.1: Demographic and clinical characteristics of deceased schizophrenic and control subjects. 
Tissue samples were obtained from the brain bank of the Institute of Psychiatry, King’s College London, 
UK. Gender, age (years), post-mortem delay (h) and the cause of death of each individual are indicated. 
The antipsychotics used by schizophrenic patients are also reported. Nr = number; PMD = post-mortem 
delay; ? = unknown. 
5.2 HPLC analysis on human samples 
Prefrontal cortex and caudate putamen samples from post-mortem brains of 7 
controls and 10 subjects with SCZ were used to evaluate the levels of D-Asp, NMDA, 
L-Asp and L-Glu. The two groups were matched for age [control vs. SCZ, 62.6±7.4 
years vs.63.2±6.1years, p=0.9484; Student’s t test], gender (χ2 test: 0.26) and post-
mortem delay [control vs. SCZ, 34.9±9.2 h vs. 51.1±7.1 h, p=0.1756; Student’s t test]. 
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To detect D-Asp, NMDA, L-Asp and L-Glu, tissue samples were purified according 
to a previously described procedure (D'Aniello et al., 2000). Briefly, each tissue was 
homogenized 1:10 (w:vol) in 0.05 M phosphate buffer pH 7.4 in presence of protease 
inhibitors and centrifuged at 3000 rpm for 10 min. The supernatant was further 
centrifuged at 14.000 rpm for 20 min and the supernatant was treated with 1 vol of 0.2 
M TCA. The sample was recentrifuged as above and the supernatant applied to the 
cation exchange AG 50 W-X8 resin (Bio-Rad). The eluate was utilized for HPLC 
determination of D-Asp, L-Asp, L-Glu and NMDA as described previously (D'Aniello 
et al., 2005). For D-Asp, L-Asp and L-Glu detection, 20 l of each sample were added 
to a mixture consisting of 0.04M pyrophosphate buffer pH 9.5, 2 g/l OPA (o-
phthaldialdehyde) and 1 g/l NAC (N-acetyl cysteine) to a final volume of 500 l 
and 50 l were loaded on HPLC column, after 2 min of incubation. The same 
procedure was followed for a standard mixture of 17 L-amino acids plus D-aspartic 
acid. In this case 0.05 nmol of each L-amino acid plus 0.025 nmol of D-Asp were 
injected. The column was eluted at 1.2 ml/min, with a gradient consisting of solution 
A (920 ml of water, 30 ml of 1 M citrate/phosphate buffer (McIlvaine buffer), pH 5.6, 
and 50 ml of acetonitrile) and solution B (90% acetonitrile in water). The program 
gradient was 0–5% solution B for 10 min; 5–30% solution B for 30 min, 30–
100%solution B for 10 min, staying at 100%solution B for 5 min and returning to 0% 
of solution B for 1 min. The fluorescence was read at an excitation wavelength of 330 
nm and an emission wavelength of 450 nm. D-Asp was eluted with a peak at 5.6 min, 
followed by L-Asp 0.5 min later and L-Glu about 1 minute later and was well separated 
from other amino acids. To verify that the peak eluted at 5.6 min was really D-Asp, 10 
μl of the sample was mixed with 20 μl of 0.5 M pyrophosphate buffer, pH 8.2, and 2 
μl of purified DDO, and incubated for 20 min at 37◦C, then 100 μl of 0.5 M 
pyrophosphate buffer, pH 9.5, and 20 μl of OPA/ NAC were added, before HPLC, as 
described above. The absence of the peak at elution time 5.6 min or its decrease 
confirmed the presence of D-Asp. The standard mixture of amino acids was carried 
out under the same conditions to give a standard curve. The areas of the peaks of amino 
acid standards were used to calculate the amount of D-Asp and other amino acids 
contained in the sample. NMDA do not have a primary amino group, so it do not react 
with OPA and are eluted immediately from the C-18column. Therefore, to detect the 
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content of NMDA we used a method based on the measurement of the CH3-NH2 
(methylamine), which is generated from the reaction between NMDA and DDO 
(D'Aniello et al., 2000), as shown by the following reaction: 
 
Therefore, for NMDA detection, 75 l of each sample were incubated with 2 l of 
bovine DDO (1 g /l), in presence of 10 l of 1M borate buffer pH 8.0, for 30 min at 
37°C. After incubation, to each sample is added 0.4 M borate buffer pH 9.5 to a final 
volume of 135 l and then 15 l of OPA-mercaptoethanol reagent (consisting of 5 mg 
OPA in 1 ml methanol and 10 l of -mercaptoethanol). After 2 min (needed to obtain 
the complete derivatization of the amino acids), 100 l of sample was injected onto a 
C-18 Supelcosil HPLC column, using the Beckman-Gold HPLC system. The column 
was eluted with a gradient consisting of solvent A (10% acetonitrile in 30 mM sodium 
acetate buffer, pH 5.5) and solvent B (70% acetonitrile in 30 mM sodium acetate 
buffer, pH 5.5) using the following gradient program: 0–40% B over 15 min; to 100% 
B in 4 min, staying at 100% B for 3 min and back 0% B in 1 min, at a flow rate of 1.2 
ml/min. CH3-NH2 was detected fluorometrically at an excitation wavelength of 330 
nm and an emission wavelength of 450 nm. The CH3-NH2 eluted as a sharp peak at 
the retention time of 21.2 min, well separated from the other amino acids. After 
running the sample, 5 ml of OPA-mercaptoethanol was added to the blank sample, 
consisting of 20 ml of sample as purified above and 20 ml of 0.1 M borate buffer, pH 
8.2, and chromatographed as with the sample. The difference of the peak areas 
obtained between the sample and the blank sample gave the net amount of the area due 
to the methylamine generated by the action with DDO. To quantify the concentration 
of NMDA in the sample, a standard curve of different concentrations of NMDA (range 
0.1–1.0 nmol/ml) was performed under the same assay conditions as the samples. 
 
5.3 Western blotting 
Frozen, powdered PFC and caudate-putamen samples from post-mortem brains 
were sonicated in 1% SDS and boiled for 10 min. Aliquots (2 μl) of the homogenates 
were used for determination of total proteins using Bio-Rad Protein Assay dye. Equal 
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amounts of total proteins (35 μg) for each sample were loaded onto 10% 
polyacrylamide gels. Proteins were separated by SDS-PAGE and transferred overnight 
to membranes (polyvinylidene difluoride) (GE Healthcare). Membranes were 
immunoblotted using antibodies against GluN1, GluN2A (1:1000, Sigma, St. Louis, 
MO, USA), GluN2B (1:1000, Millipore, Billerica, MA, USA) and GAPDH (1:1000, 
Santa Cruz Biotechnology, Santa Cruz, CA, USA). Blots were then incubated in 
horseradish peroxidase-conjugated secondary antibodies. Target proteins were 
visualized by ECL detection (Pierce) and quantified by Quantity One software (Bio-
Rad). Optical density values were normalized to GAPDH for variations in loading and 
transfer. Means and SEM of normalized values were then compared using non-
parametric Mann-Whitney test. The analysis of GluN1 was performed on 15 control 
and 14 SCZ subjects in the prefrontal cortex and on 14 control and 13 SCZ subjects in 
the caudate putamen. In both brain areas, the two groups were matched for age 
[prefrontal cortex: control vs. SCZ (mean±SEM), 63.3±4.6 years vs. 61.7±5.1 years, 
p=0.8228; caudate putamen: control vs. SCZ (mean±SEM), 64.3±4.8 years vs. 
60.4±5.3 years, p=0.5913; Student’s t test] and gender (χ2 test: prefrontal cortex, 0.86; 
caudate putamen, 0.84). The post-mortem delay was significantly longer in SCZ 
patients compared to the control group [prefrontal cortex: control vs. SCZ 
(mean±SEM), 35.1±5.7 h vs. 58.8±6.8 h, p=0.0120; caudate putamen: control vs. SCZ 
(mean±SEM), 35.3±6.1 h vs. 58.7±7.5 h, p=0.0223; Student’s t test]. The analysis of 
GluN2A was performed on 15 control and 15 SCZ subjects in the prefrontal cortex 
and on 15 control and 12 SCZ subjects in the caudate putamen. In both brain regions, 
the two groups were matched for age [prefrontal cortex: control vs. SCZ (mean±SEM), 
63.3±4.6 years vs. 61.7±4.8 years, p=0.8186; caudate putamen: control vs. SCZ 
(mean±SEM), 63.3±4.6 years vs. 61.3±5.7 years, p=0.7918; Student’s t test] and 
gender (χ2 test: prefrontal cortex, 1; caudate putamen, 0.86). The post-mortem delay 
was significantly greater in SCZ patients, compared to control group [prefrontal 
cortex: control vs. SCZ (mean±SEM), 35.1±5.7 h vs. 57.2±6.5 h, p=0.0160; caudate 
putamen: control vs. SCZ (mean±SEM), 35.1±5.7 h vs.55.0±7.1 h, p=0.0374; 
Student’s t test]. The analysis of GluN2B was performed on 11 control and 10 SCZ 
subjects in the prefrontal cortex and on 6 control and 4 SCZ subjects in the caudate 
putamen. In the caudate putamen, the two groups were matched for age [control vs. 
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SCZ (mean±SEM), 76.3±4.2 years vs. 67.2 ±2.4 years, p=0.4373; Student’s t test], 
gender (χ2 test: 0.60) and post-mortem delay [control vs.SCZ (mean±SEM), 36.5±10.2 
h vs.55.5±14.8 h, p=0.3042; Student’s t test]. In the prefrontal cortex, control and SCZ 
groups were matched for gender (χ2 test: 0.80), while age of SCZ subjects was 
significantly younger and the post-mortem delay significantly longer compared to the 
respective control groups [age effect: control vs. SCZ (mean±SEM), 71.6±3.3 years 
vs. 56.1±5.7 years, p=0.0254; post-mortem delay effect: control vs. SCZ 
(mean±SEM), 38.4±7.0 h vs .63.4±9.6 h, p=0.0450; Student’s t test]. 
 
5.4 Quantitative reverse transcription-polymerase chain reaction analysis in 
humans 
Total RNA was extracted using miRNeasy® kit (Quiagen, Hilden, Germany) 
according to the manufacturer’s instructions. RIN of samples was assessed using 
Biorad Experion Automated electrophoresis Station (Hercules, CA) prior to cDNA 
synthesis with Transcriptor First Strand cDNA Synthesis kit (Roche Diagnostics, 
Mannheim, Germany). Total RNA (0.5 μg per sample) was used to synthesize cDNA. 
Quantitative RT-PCR with Real Time ready catalog Assays (Roche Diagnostics) and 
LightCycler® 480 Probe Master (Roche Diagnostics) was performed on a Light Cycler 
480 II Real Time PCR system with 96-well format (Roche Diagnostics). All 
measurements from each subject were performed in duplicate. DDO mRNA 
expression levels were normalized to the geometric mean of three housekeeping genes:  
β-actin, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and cyclophilin 
(PPIA). The following primers were used for DDO cDNA amplification: DDO fw  5’-
GGTGTTCATTTGGTATCAGGTTG-3’ and DDO rev 5’-
TTTCGAAATCCCAGAACCA-3’; β-actin fw 5’- TCCTCCCTGGAGAAGAGCTA-
3’ and β-actin rev 5’-CGTGGATGCCACAGGACT-3’; GAPDH fw 5’- 
AGCCACATCGCTCAGACAC -3’ and GAPDH rev 5’-
GCCCAATACGACCAAATCC  -3’; PPIA fw 5’-TTCATCTGCACTGCCAAGAC -
3’ and PPIA  rev 5’- CACTTTGCCAAACACCACAT -3’. Changes in DDO mRNA 
expression of SCZ, compared with Ctrl, were calculated using the relative 
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quantification method (2−ΔΔCt) and used as dependent variable. Data were analyzed 
using analysis of covariance with diagnosis as the predictor. Postmortem delay was 
modeled as covariate of no interest. 
 
5.5 Methylation analysis 
Methylation status of the putative DDO promoter was assessed through a 
strategy on the basis of the locus-specific amplification of bisulfite-treated genomic 
DNA. Sodium bisulfite conversion was performed by using EZ DNA Methylation Kit 
(Zymo Research). The manufacture’s protocol was followed by using 2 µg of genomic 
DNA and eluted in 30 µl of H2O. The average conversion rate was 99.1%. Methylation 
status was assessed through a strategy based on the locus-specific amplification of 
bisulfite-treated genomic DNA, amplifying each amplicon separately, followed by 
Roche 454 resequencing. Fusion primers were designed to generate tiled amplicons 
ranging in size between 300-400 bp segments. Fusion primers used for this analysis 
were: DDO fw 5’-aTTtaTaaatTagTtggagaaagTTTag-3’ and DDO rev 5’-
cacaAtAAcctAtccatcactAtcc-3’ (where the capital letters indicate the original C or G, 
respectively). At the 5′ end, fusion primers contained an additional sequence, MID, 
that barcodes the sample. The MID sequence was selected from a list provided from 
Roche. Thermal cycling was performed as follows: one cycle at 95 °C for 2 min 
followed by 40 cycles at 95 °C for 30 s, at the specific annealing temperature for 30 s, 
at 72 °C for 50 s, followed by a final extension step at 72 °C for 6 min. Small DNA 
fragments were removed using AMPure PCR purification system (Agencourt, 
Beverly, MA, USA) following the manufacturer's protocol. Amplicons were 
quantified using the Quant-iT PicoGreen dsDNA reagent (Invitrogen Corporation, 
Life Techologies, Carlsbad, CA, USA). All amplicons were pooled at an equimolar  
ratio  and  the  sample  pool  was  diluted  to  a  final  concentration  of  1  ×  107 PCR 
molecules/μl.  The  amplicon  fragments  were  annealed  to  carrier  beads  and  clonally  
amplified  by emulsion PCR (emPCR). emPCR was performed according to the 
manufacturer's protocol. The beads were isolated and compartmentalized into droplets 
of an aqueous PCR reaction buffer in oil emulsion. Subsequently,  the  emulsions  were  
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broken  by  isopropanol  to  facilitate  collection  of  the amplified  fragments  bound  
to  their  specific  beads.  The beads carrying single-stranded DNA templates were 
enriched, counted and deposited into the PicoTiterPlate for sequencing. Data analysis 
was performed using the Roche proprietary software package for the GS Junior 
system. Post-run analysis was conducted using the version 2.7 of GS Amplicon Variant 
Analyzer. In this study, amplicon nucleotide sequence reads were aligned to the human 
genomic sequence of DDO. The AVA software identified all nucleotide variants, and  
provided read counts and frequencies. Individual flow grams were reviewed to 
examine and confirm all variant calls made by the software.  Methylation analysis of 
one patient and one control subject gave no results and thus were excluded. The 
average number of molecules analyzed for subject was 207/sample for a total number 
of 11.818 reads. Data were analyzed using analysis of covariance with diagnosis as the 
predictor. Postmortem delay was modeled as covariate of no interest. 
 
5.6 Animals 
Knockout male mice for the Ddo gene were generated and genotyped by PCR 
as described previously (Errico et al., 2006). C57BL/6J  male  mice  were  purchased  
from  the  Jackson  Laboratory  (Bar  Harbour,  ME,  USA).  Animals were either 
chronically administered with D-Asp by delivering the D-amino acid (20 mM) in 
drinking water for 1 month, or acutely administered by intra-peritoneal (i.p.) injection 
(500 mg/kg D-Asp, dissolved in 0.9% NaCl). Animals were group housed (five per 
cage), at a constant temperature (22±1 °C) on a 12 h light/dark cycle (lights on at 7 
AM) with food and water ad libitum. All research involving animals was carried out 
in accordance with the European directive 86/609/EEC governing animal welfare and 
protection, which is acknowledged by the Italian Legislative Decree no. 116, 27 
January 1992. Every effort was made to minimize suffering of the animals. Animal 
research protocols were also reviewed and consented to by a local animal care 
committee. 
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5.7 LC-MS/MS 
All molecules were purchased from Sigma-Aldrich. All the solutions and 
solvents were of the highest available purity and were suitable for LC–MS analysis 
and purchased from J. T. Baker (Phillipsburg, NJ). All stock solutions were stored at 
−20 °C.  Tissue samples derive from Ddo-/- mice. 
The spiking standard was prepared by adding 1.00 mL aliquots of each molecule to a 
10-mL volumetric flask and bringing the standard to volume with methanol to yield a 
standard with 1000 ng/mL of each molecule. The spiking standard should be stored at 
−20 °C until the analysis. This was used to correct the recoveries of the different 
analytes. 
Stock solutions were prepared, for each metabolite standard at a concentration of 1.0 
mg/mL in methanol. Final 2 μg/mL individual metabolite standard solutions were 
prepared, by serious dilution from stock, and were used for mass spectrometric tuning. 
A standard mixture of all metabolites at 5, 10, 25, 50, 100, 200, 300, 500 pg/ul for 
metabolites having higher, medium, and lower measuring sensitivities, respectively, 
under current experimental condition, was prepared, from individual standard stock 
solution, and then used to generate lower concentration levels via series dilutions for 
linearity assessment. 
All tissues were homogenized by sonication in Tris buffer pH 8, and stored at −20 °C 
until the time of analysis. For an initial screening extraction batch run, the control 
tissue was fortified in triplicate at the 200 pg/ul target level by adding the spiking 
standard solution to a 4.0-g portion of control tissue. Aliquot of 0.6 ml of methanol 
was added (0.2ml) to each sample and the tube was mechanically shaken vigorously 
for 5 min. The tube was centrifuged at 10000 rpm (7600 rcf) at 10 C for 10 min. Using 
a Pasteur pipette, the upper organic layer was transferred into a centrifuge tube. 0.2ml 
of upper organic layer was filtered through a 0.2-μm PTFE syringe filter (Pall Acrodisc 
13 mm) into an LC vial for analysis. 
Two ul of supernantant were analysed by using a 6420 triple Q system with a HPLC 
1100 series binary pump (Agilent, Waldbronn, Germany). The enantiomers were 
separated by using as analytical column an Astec chirobiotic T column 10 cm x 4,6mm, 
5u. The mobile phase was generated by mixing eluent A (0.1 % Formic Acid in 2% 
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ACN) and eluent B (0.009 % Formic Acid in methanol) and the flow rate was 0.500 
mL/min. Starting condition was 50% to 95% B in 6 min. 
Tandem mass spectrometry was performed using a turbo ion spray source operated in 
positive mode, and the multiple reaction monitoring (MRM) mode was used for the 
selected analytes.  A standard solution of 500 pg/ul of each metabolite was used for 
optimization of the MRM transition reported in Table 5.1.  
 
Table 5.1: MRM transition 
 
Metabolites were automatically (flow injection) tuned for ionization polarity, optimal 
declustering potential (DP), product ion, and collision energy (CE) using metabolite 
standard solutions via Agilent MassHunter Optimizer software. Table 5.1 provides a 
list of precursor ion, product ions, collision energy and retention times for all analytes.  
Extracted mass chromatogram peaks of metabolites were integrated using Agilent 
MassHunter Quantitative Analysis software (B.05.00). Peak areas of corresponding 
metabolites are then used, as quantitative measurements, for assay performance 
assessments such as assay variation, linearity etc.  
5.8 Golgi-Cox staining and dendritic spine measurements 
Golgi-Cox staining was performed on brains of naive animals, according to a 
previous protocol (D'Amelio et al., 2011). Fully impregnated pyramidal neurons laying 
in the PFC and in the CA1 region of the dorsal hippocampus were visualized at × 100 
(oil-immersion) using a microscope (DMLB, Leica Biosystems) equipped with a 
camera (resolution = 2600 × 2600, Axiocam, Zeiss AG, Oberkochen, Germany), and 
the KS300 3.0 system (Zeiss). A computer-based neuron tracing system (Neurolucida, 
Microbrightfield, MBF Bioscience, Williston, VT, USA) was used to trace single 
neurons. Total dendritic length and spine density were calculated according to 
D’Amelio et al., 2011 and analyzed using Student’s t-test. Dendritic complexity was 
calculated according to Balu et al. (Balu and Coyle, 2012) and analyzed using two-
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way analysis of variance with repeated measures, followed by Fisher’s post hoc 
comparison when required. 
 
5.9 Electrophysiology 
Coronal slices from mouse medial PFC (mPFC; 250μm) were cut in ice-cold 
artificial cerebrospinal fluid using standard procedures. Visually guided whole-cell 
recordings were performed as previously described (Nistico R, Mango D, Mandolesi 
G, Piccinin S, Berretta N, Pignatelli M et al. Inflammation subverts hippocampal 
synaptic plasticity in experimental multiple sclerosis.PLoS One2013;8: e54666) using 
1.5 mm borosilicate glass electrodes (3–4MΩ) filled with a solution containing (in 
mM) CsMeSO4(130), HEPES (5.0), EGTA (0.5), MgCl2(1.0), NaCl (1.0), 
CaCl2(0.34), QX-314 (5.0), adjusted to pH 7.3 with CsOH. Miniature excitatory 
postsynaptic currents (mEPSCs) were collected from layer II/III mPFC pyramidal 
neurons and NMDA currents were pharmacologically isolated according to a 
previously described procedure (Rompala GR, Zsiros V, Zhang S, Kolata SM, 
Nakazawa K. Contribution of NMDA receptor hypofunction in prefrontal and cortical 
excitatory neurons to schizophrenia-like phenotypes.PLoS One2013;8: e61278).For 
extracellular recordings, parasagittal hippocampal slices (thickness, 400μm) were cut 
using a Vibratome (Leica VT1000 S, Leica Biosystems, Wetzlar, Germany). Slices 
were incubated for 1 h in a holding chamber and then transferred to a recording 
chamber, completely submerged in artificial cerebrospinal fluid (30–31 °C) of the 
following composition (in mM): NaCl (124), KCl (3.0), MgCl2 (1.0), CaCl2(2.0), 
NaH2PO4(1.25), NaHCO3 (26), glucose (10); saturated with 95% O2, 5% CO2. Bipolar 
stimulating electrodes placed in the stratum radiatum to activate the Schaffer collateral 
commissuralfibers. Recordings offield excitatory postsynaptic potentials were made 
in the middle of the stratum radiatum by using microelectrodesfilled with artificial 
cerebrospinalfluid (resistance 3–5MΩ). LTP was induced with 1 s, 100 Hz stimulation. 
For statistical analysis we used unpaired t-tests after LTP induction (on the average of 
the last 10 min of recording). 
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5.10 PCP-induced motor activity 
The procedure used has been previously described (Errico et al., 2008a). PCP 
(Sigma, St Louis, MO, USA) was dissolved in distilled water at the dose of 3 and 6 
mg/kg in a volume of 10 ml/kg. After 1 h of habituation to the test cage (35 × 25 × 30 
cm), PCP (3 and 6 mg/kg) or vehicle were injected intraperitoneally to male 3-month-
old Ddo+/+ and Ddo−/− mice and locomotion, expressed in cm, recorded over 1 h by 
using a computerized video tracking system (Videotrack; Viewpoint, Lyon, France). 
Motor response to PCP was evaluated by three-way analysis of variance (ANOVA; 
genotype × treatment × time) with repeated measures, followed by twoway ANOVA 
(genotype × time) with repeated measures. 
5.11 Prepulse inhibition of the startle reflex under PCP treatment 
Ddo−/− and D-Asp-treated mice, and their respective control groups (Ddo+/+ and 
H2O-treated mice, respectively), were assigned to receive either PCP (3 and 6 mg/kg) 
or vehicle (balanced for genotype and startle chamber assignment) and placed in a 
Plexiglas cylinder within the startle chamber 10 min after intraperitoneal injection. 
Prepulse inhibition (PPI) was measured using an SR-Lab System as previously 
described (Errico et al., 2008c). We chose to test 70, 74, 78 and 82 dB prepulse sounds 
(5, 9, 13 and 17 dB above background, respectively). PPI data were analyzed within 
genotype using two-way ANOVA (treatment × prepulse sound levels) with repeated 
measures. 
5.12 Functional and pharmacological magnetic resonance imaging 
Resting-state and pharmacological functional magnetic resonance imaging 
(fMRI) (Ferrari et al., 2012; Sforazzini et al., 2014)were performed on male 3–4-
month-old Ddo−/− mice (n=9) and Ddo+/+ littermates (n= 12). An additional 
pharmacological fMRI study was carried out on 4-month-old male C57BL/6-J mice 
treated with D-Asp (n= 10) or water (n= 10) for 1 month. Briefly, mice were intubated, 
artificially ventilated and imaged under halothane (0.7%) anesthesia. Mean blood 
pressure, paCO2 and paO2 levels were recorded to rule out non-physiological states. 
MRI acquisitions were carried out at 7.0 Tesla. For each session, high-resolution 
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anatomical images were followed by a co-centered single-shot BOLD fMRI time 
series. The functional effect of PCP was mapped using a pharmacological fMRI as 
previously described (Gozzi et al., 2008c; Gozzi et al., 2008b; Dodero et al., 2013). 
fMRI time series were sensitized to cerebral blood volume using a blood-pool contrast 
agent, and 15 min later each subject received an intra-arterial injection of PCP (1 
mg/kg). To assess the modulatory role of D-Asp elevation in wild-type mice, an 
additional pharmacological fMRI study with PCP was performed in C57BL/6-J mice 
exposed to D-Asp (20 mM in tap water) or vehicle (plain water) for 1 month (n= 10 
each group). Inter-strain differences in resting-state fMRI (rsfMRI) correlation 
networks were mapped and quantified using a seed-based approach as recently 
described (Sforazzini et al., 2014; Zhan et al., 2014). Small a priori seed regions were 
chosen to cover antero–posterior cortical and hippocampal networks. The fMRI 
response to PCP was mapped and quantified as previously described (Gozzi et al., 
2008c; Gozzi et al., 2008b; Gozzi et al., 2008a). Relative cerebral blood volume time 
series before (8 min) and after drug or vehicle injections (24 min) were extracted and 
voxel-wise group statistics were performed using FEAT Version 5.63 with 0.5 mm 
spatial smoothing and family-wise cluster correction threshold of 0.001. 
 
5.13 In vivo microdialysis 
Microdialysis experiments were performed in awake and freely moving mice 
as previously reported (Guida et al., 2015). Briefly, 3/4-month-old C57BL/6J mice 
were anaesthetized with pentobarbital (50  mg/kg,  i.p.)  and  stereotaxically  implanted  
with  concentric  microdialysis  probes  into  the  PFC using the following coordinates 
AP: 1.8 mm; L: 0.4 mm from bregma and V: 3.0 mm below the dura,  and secured to 
the skull using stainless steel screws and dental cement.  Microdialysis probes were 
constructed with 22G (0.41 mm I.D., 0.7 mm O.D.) stainless steel tubing: inlet and 
outlet cannulae (0.04 mm I.D., 0.14 mm O.D.) consisted of fused silica tubing. The 
probe had a tubular dialysis  membrane  (Enka  AG,  Wuppertal,  Germany)  1.3  mm  
in  length.  After  a  post-operative recovery period of 24 hours, probes  were perfused 
at  1  μL/min with artificial cerebrospinal fluid (ACSF: 147 mM NaCl, 2.2 mM CaCl2, 
4 mM KCl; pH 7.2) by a Harvard Apparatus (Holliston, MA, USA) infusion pump. 
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After an  equilibration period of 60 min,  dialysated  samples  were collected every 20 
or 30 min depending on the route of D-Asp administration (acute or chronic), and were 
then analyzed for D-Asp, L-Asp and L-Glu content as detailed below. Conversely,  
samples collected in the absence of calcium were obtained by perfusing with Ca2+-free 
ACSF solution. Olanzapine was dissolved in distilled water and administered i.p. (5 
mg/kg) for 4 weeks. Chronic treatments with olanzapine or D-Asp were interrupted 24 
hours before microdialysis. 
 
5.14 High-performance liquid chromatography analysis 
Dialysates were analyzed for D-Asp, L-Asp and L-Glu content by high-
performance liquid chromatography (HPLC) coupled with a fluorimetric detection 
method as previously described (Guida et al., 2015). In this case, the HPLC system 
comprised a Varian ternary pump (mod. 9010), a C18 reverse-phase column, a Varian 
refrigerated autoinjector (mod. 9100), a Varian fluorimetric detector. Dialysates were 
precolumn derivatized with OPA (10 μL dialysate + 10 μL OPA) and amino acid 
conjugates resolved using a gradient separation. The mobile phase consisted of 2 
components: a) 0.2 M sodium phosphate buffer pH 5.8, 0.1 M citric acid, and b) 90% 
acetonitrile, 10% distilled water. Additionally, to determine the peak area 
corresponding to D-Asp, selected samples were incubated in parallel with 20 µg of 
recombinant beef DDO for 15 min at 37 °C and analyzed  as above. The 
disappearance/reduction of the area of D-Asp elution peak confirmed the presence of 
D-Asp and gave the exact D-Asp  content. Data were collected by a Dell Corporation 
PC system 310 interfaced by Varian Star 6.2 control data and acquisition software. D-
Asp and L-Asp total content in PFC homogenates was accomplished as previously 
reported (Topo et al., 2010), with minor modifications. Tissue samples were 
homogenized in 1:20 (w/v) 0.2 M TCA, sonicated (3 cycles, 10 s each) and centrifuged 
at 10000 g for 10 min. The precipitated protein pellets were stored at -80 °C for protein 
quantification, while the supernatants were neutralized with NaOH, derivatized with 
OPA/NAC and analyzed on a Symmetry C8 5 µm, 4.6x250 mm column (Waters, 
Milford, MA, USA). Identification and quantification of D-Asp and L-Asp, was based 
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on retention times and peak areas, compared with those associated with external 
standards. The identity of D-Asp and L-Asp peaks was confirmed either by the 
addition of internal standards, and by a pre-column treatment with RgDAAO  M213R 
variant (which is active on acidic D-amino  acids) (Sacchi et al., 2002) and StLASPO 
(active on L-Asp) (Bifulco et al., 2013), respectively: the samples were added with 10 
µg of the enzymes, incubated at 30 °C for 30 min and then derivatized. Calibration 
curves were built by injecting increasing amount of standards (0.25-50 pmoles). Total 
protein content of PFC homogenates was determined by using the Bradford assay 
method, after resolubilization  of  the  TCA  precipitated  protein  pellets. The detected 
D-Asp and L-Asp total concentration in PFC homogenates was normalized by the total 
protein content; whereas amino acids  extracellular levels were expressed as nM or 
µM concentration. 
5.15 Synaptosomes preparation 
Synaptosomes  were isolated from the mouse frontal cortex as previously 
described (Marti et al., 2003; Mela et al., 2004; Cristino et al., 2015). The 
synaptosomal pellet was resuspended in oxygenated (95% O2, 5% CO2) Krebs solution 
(mM: NaCl 118.5, KCl 4.7, CaCl2 1.2, MgSO4 1.2, KH2PO4 1.2, NaHCO3 25, glucose 
10). One mL aliquot of the suspension (~0.35 mg protein) was slowly injected into 
nylon syringe filters (outer diameter 13 mm, 0.45 µM pore size, internal volume of 
about 100 µL; Teknokroma, Barcelona, Spain) connected to a peristaltic pump. Filters 
were maintained at 36.5 °C, connected to a peristaltic pump and superfused at a flow 
rate of 0.4 mL/min with a pre-oxygenated Krebs  solution  containing  the  excitatory  
amino  acid  transporter  inhibitor  DL-threo-β-benzyloxyaspartic acid (TBOA, 10 
µM), to prevent  L-Glu  release from transport reversal. Sample collection (every 3 
min) was initiated after a 20 min period of filter washout. The effects of D -Asp (10 
µM), L-Asp (10 µM) and NMDA (10 µM) were evaluated on 15 mM K+-stimulated 
(90 s pulse) neurotransmitter outflow. Agonists were added to the perfusion medium 
3 min prior to K+ and maintained in the perfusion fluid for an additional 3 min. The 
NMDAR antagonist MK-801 (10 µM), the AMPA/kainate receptor antagonist CNQX 
(0.3 µM) and the mGlu5 receptor (mGluR5) negative allosteric modulator MTEP (0.3 
µM) were perfused 3 min prior to agonists and maintained until the end of experiment.  
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5.16 Enzymes and inhibition assays   
Recombinant M213R variant of Rhodotorula gracilis  D-amino acid oxidase 
(referred to as RgDAAO; EC 1.4.3.3) and Sulfolobus tokodaii L-aspartate oxidase 
(referred to as StLASPO; EC 1.4.3.16) were overexpressed in E. coli cells and purified 
as previously described (Sacchi et al., 2002; Bifulco et al., 2013). The final M213R 
RgDAAO and StLASPO preparations had a specific activity of 5.8 U/mg protein on 
D-Asp and 0.9 U/mg protein on L-Asp, respectively.  Recombinant DDO (EC 1.4.3.1) 
from beef kidney was expressed in  E. coli and the purified preparation showed a 
specific activity of 5 U/mg protein  on D-Asp  (Negri et al., 1999).  These 
flavoenzymes were fully inactive on the opposite enantiomers. Recombinant D-
aspartate oxidase from mouse (mDDO) and human (hDDO) origin were overexpressed 
in  E. coli  cells and purified as previously reported (Katane et al., 2015), with minor 
modifications. The effect of olanzapine and clozapine on DDO activity was evaluated 
by using a coupled enzyme assay and the Amplex UltraRed reagent (Life  
technologies, Carlsbad, CA USA) as previously described (Hopkins et al., 2013; 
Terry-Lorenzo et al., 2014). In details, 0.17 U/mL of mDDO or hDDO and 0.1 U/mL 
horseradish peroxidase (Roche, Basel, Switzerland) were incubated for 30 min with 
olanzapine or clozapine (0  -  320 µM) in the presence of exogenous FAD (4  or 100  
µM)  in  50 mM sodium phosphate, pH 7.4, 0.06 mg/mL human serum albumin, 0.8% 
(w/v) DMSO; then D-Asp (7.5 mM) and the Amplex UltraRed reagent (35 μM) were 
added and reaction proceeded for 30 min. The fluorescence of oxidized Amplex 
UltraRed produced by DDO activity was measured in endpoint  mode (using  540 and 
595 nm as excitation and emission wavelengths, respectively). All enzymatic assays 
were conducted at room temperature in 96-well plate format using an automated 
liquid-handler system (epMotion 5075; Eppendorf, Hamburg, Germany). Data were 
fit to a standard, four parameters equation to determine curve top, bottom, 
concentration producing 50% inhibition (IC50) and Hill  slope (Hopkins et al., 2013; 
Terry-Lorenzo et al., 2014).   
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